Antigen binding protein

CD96 binding proteins are developed to address the limited understanding of CD96 in immunotherapy, offering a means to inhibit CD96 activity and enhance cancer treatment by blocking its interactions with CD155, thus modulating immune responses and improving therapeutic efficacy.

JP2024167261AInactive Publication Date: 2024-12-03GLAXOSMITHKLINE INTPROP DEV LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024139180
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-07-28
Filing Date
2024-08-20
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of effective antigen-binding proteins targeting CD96 for treating diseases, particularly in the context of cancer, as the function of CD96 remains poorly understood compared to CD226 and TIGIT, and existing immunotherapies for CD96 are limited.

Method used

Development of CD96 binding proteins, nucleic acids encoding these proteins, and related expression vectors and host cells for producing CD96 binding proteins, which can be used in pharmaceutical compositions to treat diseases by interfering with CD96 activity.

Benefits of technology

The CD96 binding proteins effectively inhibit CD96 function, modulating immune responses and enhancing cancer treatment by blocking CD96 interactions with CD155, thereby improving therapeutic outcomes in cancer models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167261000017
    Figure 2024167261000017
  • Figure 2024167261000018
    Figure 2024167261000018
  • Figure 2024167261000019
    Figure 2024167261000019
Patent Text Reader

Abstract

To provide a composition for treating CD96-mediated disease, and a related method.SOLUTION: Provided are a CD96 binding protein including: (a) (i) any one or a combination of CDR selected from CDRH1, CDRH2, CDRH3 from a specific sequence and / or CDRL1, CDRL2, CRDL3 from the specific sequence; or (ii) a CDR variant of (i) which has 1, 2, or 3 amino acid modifications; or (b) a VH region including a sequence at least 80% identical with the specific sequence; and / or a VL region including a sequence at least 80% identical with the specific sequence, and a pharmaceutical composition including the CD96 binding protein and a pharmaceutically acceptable excipient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antigen binding proteins and fragments thereof that specifically bind to CD96, in particular human CD96. The invention also relates to methods of treating diseases or disorders with the antigen binding fragments, pharmaceutical compositions comprising the antigen binding fragments, and methods of manufacture. Other embodiments of the invention will become apparent from the following description. [Background technology]

[0002] CD96 / TACTILE ("T cell activation increased late expression") is a cell surface receptor in the immunoglobulin superfamily, expressed primarily on T cells, natural killer (NK) cells, and natural killer T (NKT) cells. CD96 belongs to a family of receptors that includes CD226 and TIGIT ("T cell immunoreceptor with Ig and ITIM domains") that are known to interact with nectins and nectin-like ligands. CD155nECL5 ("nectin-like protein-5") is the primary ligand for all three receptors (CD96, TIGIT, and CD226). TIGIT binds CD155 with higher affinity (3.15 nM) than CD226 (119 nM), with CD96 binding intermediate (37.6 nM) (Martinet L. & Smyth MJ Nat Rev Immunol. 2015 Apr; 15(4): 243-54). In addition to CD155, both TIGIT and CD226 bind to another ligand, CD112, with much lower affinity. Recently, a new receptor, CD112R, that also binds to CD112 was discovered (Zhu Y., et al. J Exp Med. 2016 Feb 8; 213(2): 167-76).

[0003] Among the receptors in this axis, CD226 (DNAM-1) is one of the major activating receptors for NK cells. CD226 has been reported to enhance NK cell cytotoxicity against cancer cells and is important for tumor immune surveillance (Lakshmikanth T., et al. J Clin Invest. 2009; 119(5): 1251-63; Chan CJ, et al. J Immunol. 2010; 184(2): 902-11; Gilfillan S., et al. J Exp Med. 2008; 205(13): 2965-73; Iguchi-Manaka A., et al. J Exp Med. 2008; 205(13): 2959-64). Conversely, both CD96 (Chan CJ, et al. Nat Immunol. 2014; 15(5): 431-8) and TIGIT (Lozano E., et al. J Immunol. 2012; 188(8): 3869-75) are known to dampen immune responses through inhibition of NK and / or T cell function. TIGIT expression is associated with T cell exhaustion (Lozano E., et al. 2012; Kurtulus S., et al. J Clin Invest. 2015; 125(11): 4053-62) and NK cell exhaustion (Zhang Q., et al. Nat Immunol. 2018; 19(7): 723-32), and several anti-TIGIT antibodies are in clinical development.

[0004] Overall, there is a much larger literature and mechanistic understanding of CD226 and TIGIT compared to CD96. CD226 does not have a classical ITAM motif as in other immune activation receptors. Upon ligand binding and receptor dimerization, it transmits positive signals through a series of phosphorylation events involving PKC and Vav1 proteins. The cytoplasmic tail of TIGIT contains an ITT motif and a classical inhibitory ITIM motif. Upon CD155 binding, tyrosine phosphorylation of the ITT motif occurs, and immune inhibitory signaling is transmitted downstream, including SHIP1. In contrast, signaling for CD96 remains to be elucidated. It is known that the cytoplasmic tail of CD96 contains a potentially inhibitory ITIM motif, as well as a potentially activating YXXM motif present in multiple immune activation receptors (e.g., ICOS and CD28) (Georgiev H., et al. Front Immunol. 2018; 9: 1072).

[0005] Although CD96 was discovered over 25 years ago (Wang PL, et al. J Immunol. 1992; 148(8): 2600-8), little was known about its function other than that it is a member of the immunoglobulin family that shares the ligand CD155 with CD226 and TIGIT (Fuchs A., et al. J Immunol. 2004; 172(7): 3994-8). Subsequent publications linking CD96 to cancer have focused primarily on CD96 as a leukemic stem cell (LSC) marker. The first paper showing CD96 as a potential immuno-oncology target was published in 2014 by Professor Mark Smyth's laboratory; CD96 was shown to compete with CD226 for CD155 binding in NK cells, and CD96 negatively regulated the production of pro-inflammatory cytokines, including IFNγ, in mice following activation with LPS (Chan CJ, et al. 2014). CD96 knockout mice and mice treated with anti-CD96 antibodies were less susceptible to MCA-induced sarcoma formation (ibid.). In the same study, blockade of CD226 or CD155 resulted in poorer outcomes, which is hypothesized to be due to loss of the CD155:CD226 activation pathway (ibid.).

[0006] Subsequently, further in vivo studies have been published supporting the inhibition of CD96 for cancer treatment (see, e.g., Blake SJ, et al. Cancer Discov. 2016; 6(4): 446-59; Brooks J., et al. 2018; 78(2): 475-88; Harjunpaeae H., et al. Oncoimmunology. 2018; 7(7): e1445949). Thus, there is a need for improved antigen binding proteins and fragments thereof that target CD96 for use in the treatment of disease. Such compositions and related methods are provided in the present disclosure. Summary of the Invention

[0007] The present invention provides in a first aspect a CD96 binding protein. The present invention also provides in a second aspect a nucleic acid construct encoding the CD96 binding protein. In a third aspect, the present invention provides an expression vector comprising a nucleic acid according to the second aspect. In a fourth aspect, the present invention provides a recombinant host cell comprising a nucleic acid or expression vector as described in the previous aspect. The present invention further provides in a fifth aspect a method of producing a CD96 binding protein, the method comprising culturing a host cell as described in the previous aspect under conditions suitable for expression of the nucleic acid sequence or vector, thereby producing a polypeptide comprising the CD96 binding protein. A sixth aspect of the present disclosure is a CD96 binding protein produced by the production method as described in the previous aspect. The present invention also provides in a seventh aspect a pharmaceutical composition comprising a CD96 binding protein as described in any one of the previous aspects and a pharma- ceutically acceptable excipient. Another aspect of the present disclosure is a method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CD96 binding protein or pharmaceutical composition as described in any one of the previous aspects. A further aspect of the disclosure is a method of treatment as described in the previous aspect, further comprising determining whether the subject expresses CD96. Another aspect of the disclosure is a CD96 binding protein or pharmaceutical composition as described in any one of the previous aspects for treating or for use in treating a disease.

[0008] The following detailed description of the preferred embodiments of the invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. [Brief description of the drawings]

[0009] [Figure 1]FIG. 1 shows the binding of CD96 binding proteins to human CD3+ T cells (A) and the ability of CD96 binding proteins to block the binding of CD155 to CHO cells expressing human CD96 (B). [Diagram 2] FIG. 2 shows solution equilibrium titration (SET) data for binding of CD96 binding proteins to human (a), cynomolgus monkey (b) or mouse (c) CD96. [Diagram 3] FIG. 3 shows binding of CD96 binding proteins to HEK cells transiently transfected with human or cynomolgus CD96 isoforms. [Figure 4] FIG. 4 shows binding of CD96 binding protein (versus isotype control) to primary human T cells (total CD3+ T cells versus CD4+ or CD8+ subsets). [Diagram 5] FIG. 5 shows binding of CD96 binding proteins to activated primary cynomolgus monkey T cells. [Figure 6] FIG. 6: CD96 internalization using imaging cytometry in CD8+ T cells after binding to human PBMCs using imaging cytometry; representative cell images of CD8+ T cells (grey=CD8 staining, white=CD96 binding protein-PE staining). [Figure 7] FIG. 7 shows that CD96 binding protein, when pre-complexed to membrane CD96 in primary human T cells, prevents binding of CD155:Fc to T cells. [Figure 8] FIG. 8 shows displacement of CD155:Fc prebound to human T cells by CD96 binding protein. [Figure 9] FIG. 9 depicts human Fcγ reporter assay data demonstrating that binding of CD96 binding proteins to CD96 on primary human T cells does not induce cross-linking and / or signaling through Fcγ receptors. [Figure 10]FIG. 10 shows human ADCC target cell killing assay data in CD4+ and CD8+ T cells; no evidence of increased cell death was observed in either CD4+ or CD8+ T cells in the presence of CD96 binding protein. [Figure 11] FIG. 11 shows human CDC target cell killing assay in CD4+ T cells; no evidence of complement-dependent cytotoxicity elicited from CD96 binding proteins was observed. [Figure 12] FIG. 12 shows EC50 data for IFNγ release of CD96 binding proteins (expressed from CHO or HEK cells) in a mixed PMBC-MLR assay. [Figure 13] FIG. 13 shows the activity of CD96 binding proteins (expressed from HEK cells) on IFNγ production in a mixed PBMC-MLR assay with or without CD4+ (A) or CD8+ (B) T cells. [Figure 14] FIG. 14 shows the effect of CD96 binding proteins on IFNγ and granzyme B secretion in a mixed PBMC-MLR assay. [Figure 15] FIG. 15 shows the frequency of IFNγ+ cells in different cell populations on day 3 in a mixed PBMC-MLR assay in the presence of CD96 binding protein and controls. [Figure 16] FIG. 16 shows the frequency of CD96+ cells in CD4+, CD8+ and NK cell populations upon treatment with CD96 binding proteins and controls in a mixed PBMC-MLR assay. [Figure 17] FIG. 17 shows the frequency of CD96 cells in CD4+, CD8+ and NK cell populations upon treatment with CD96 binding proteins and controls in a mixed PBMC-MLR assay. [Figure 18] FIG. 18 shows FACs characterization showing the effect of CD96 binding proteins on the ratio of CD226+ single positive NK cells to CD226+CD96+ double positive NK cells in a mixed PBMC-MLR assay. [Figure 19]FIG. 19 shows FACs characterization showing the effect of CD96 binding proteins on IFNγ+GrzB+ double positive cells among the total NK cell population in a mixed PBMC-MLR assay. [Figure 20] FIG. 20 shows the inhibitory effect of plate-bound CD155-Fc on IFNγ production in a human PBMC assay. [Figure 21] FIG. 21 shows the activity of CD96 binding proteins alone or in combination with anti-PD1 or anti-TIGIT antibodies in a renal cancer TIL functional assay. [Figure 22] FIG. 22 shows bioluminescence imaging study data of CD96 binding proteins in an NK cell-dependent B16F10 melanoma lung colonization model, showing representative bioluminescence images acquired approximately 15 minutes after injection of B16F10 RFluc melanoma cells. [Diagram 23] FIG. 23 shows lung bioluminescence signal 14 days after B16F10 cell injection in mice with or without depletion of CD4, CD8, or NK cells. [Figure 24] FIG. 24 shows in vivo bioluminescent lung signals at days 14 and 20 showing the effect of CD96 binding proteins (versus control group) on lung metastases in various groups. [Diagram 25] FIG. 25 shows images of CD4+ / CD8+ depleted mouse lungs treated with CD96 binding protein versus control groups on day 20 (end of study). [Figure 26] FIG. 26 shows IFNγ production in CD155-coated PBMC assays in the presence of CD96 binding protein or isotype control in the presence of anti-TIGIT mAb as assessed by MSD. [Figure 27] FIG. 27 shows TNFα production in CD155-coated PBMC assays in the presence of CD96 binding protein or isotype control in the presence of anti-TIGIT mAb as assessed by MSD. [Figure 28]FIG. 28 shows IFNγ production in CD155-coated PBMC assays in the presence of CD96 binding protein or isotype control in the presence of anti-TIGIT mAb as assessed by MSD. Detailed Description of the Invention

[0010] The present disclosure provides CD96 binding proteins, nucleic acids encoding the proteins, and related subject matter.

[0011] As used in the specification and claims, the singular forms "a," "an," "and," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a peptide chain" is a reference to one or more peptide chains and includes equivalents thereof known to those skilled in the art.

[0012] As used in the specification and claims, the term "comprising" includes "including" or "consisting", e.g., a composition "comprising" X may consist only of X or may include something additional, e.g., X+Y.

[0013] The term "consisting essentially of" limits the scope of the feature to the materials or steps specified and to those materials or steps that do not materially affect the basic characteristics of the claimed feature.

[0014] The term "consisting of" excludes the presence of any additional component or components.

[0015] Unless otherwise defined to the contrary, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. In carrying out or testing the methods of the present disclosure, the compositions and methods described herein or any equivalent compositions and methods can be used, but exemplary compositions and methods are described herein. Any of the aspects and embodiments of the present disclosure described herein may also be combined. For example, the subject matter of any dependent or independent claim disclosed herein may be combined in multiples (e.g., one or more statements from each dependent claim may be combined into a single claim based on the independent claim to which they depend).

[0016] The ranges provided herein include all values ​​within the particular ranges described, as well as the values ​​for the endpoints of the particular ranges. The figures and tables of this disclosure also describe ranges and discrete values ​​that may constitute any of the elements of the methods disclosed herein.

[0017] The concentrations described herein are determined at ambient temperature and pressure. This may be, for example, at room temperature or within a particular portion of the process stream. Preferably, the concentrations are determined at standard conditions of 25° C. and 1 bar pressure.

[0018] The term "about" means a value within two standard deviations of the mean for any particular measurement.

[0019] "Affinity" is the strength of binding of one molecule to another. The binding affinity of an antigen-binding protein to its target can be determined by equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA)) or kinetics (e.g., BIACORE™ analysis).

[0020] The term "antigen" as used herein refers to a macromolecular structure that is selectively recognized by an antigen-binding protein. Antigens include, but are not limited to, proteins (with or without polysaccharides) or protein compositions that contain one or more T-cell epitopes. As contemplated herein, the target binding domain of an antigen-binding protein may recognize a sugar side chain of a glycoprotein rather than a specific amino acid sequence or macromolecule. Thus, a sugar moiety or a sulfated sugar moiety functions as an antigen.

[0021] The term "antigen binding protein" as used herein refers to isolated proteins, antibodies, antibody fragments (e.g., Fabs, etc.) and other antibody-derived protein constructs, such as those that contain a domain (e.g., domain antibodies, etc.) capable of binding to CD96. Such alternative antibody formats include triabodies, tetrabodies, miniantibodies, and minibodies. Also included are alternative scaffolds in which one or more CDRs of any molecule according to the present disclosure may be placed on a suitable non-immunoglobulin protein scaffold or skeleton, such as an affibody, SpA scaffold, LDL receptor class A domain, avimer (see, e.g., U.S. Patent Application Publication Nos. 2005 / 0053973, 2005 / 0089932, 2005 / 0164301), or EGF domain. ABPs also include antigen-binding fragments of such antibodies or other molecules. Additionally, the ABP may comprise a VH region of the invention formatted into a full length antibody, (Fab')2 fragment, Fab fragment, bispecific or biparatopic molecule or equivalent thereof (e.g., scFv, bi-, tri-, or tetra-body, Tandab, etc.) when paired with an appropriate light chain. The ABP may comprise an antibody that is IgG1, IgG2, IgG3, or IgG4; or IgM; IgA, IgE, or IgD, or modified variants thereof. The constant domain of the antibody heavy chain may be selected accordingly. The light chain constant domain may be a kappa or lambda constant domain. The ABP may also be a chimeric antibody of the type described in WO 86 / 01533, comprising an antigen binding region and a non-immunoglobulin region. The antigen binding protein of the present disclosure may be provided as a lyophilized powder containing the antibody and excipients that can be reconstituted with a pharma- ceutically acceptable carrier (e.g., sterile water). This reconstituted pharmaceutical composition can then be administered (e.g., with further dilution) either subcutaneously or intravenously. The antigen binding proteins of the present disclosure can also be provided as a liquid formulation containing the antibody, excipients, and a pharma- ceutical acceptable carrier. This liquid pharmaceutical composition can then be (e.g., further diluted) The antibody may be administered either subcutaneously or intravenously (through a peptide bond). The terms "ABP", "antigen binding protein" and "binding protein" are used interchangeably herein. As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to a compound composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limit is placed on the maximum number of amino acids that a protein or peptide sequence may contain. A polypeptide includes any peptide or protein that contains two or more amino acids bonded together by peptide bonds. As used herein, the term refers to both short chains (also commonly referred to in the art as peptides, oligopeptides and oligomers, for example) and longer chains (commonly referred to in the art as proteins), many of which exist. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, mutants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.

[0022] The term "antibody variant" as used herein refers to an antibody that differs from a parent antibody by at least one amino acid modification (e.g., by having a different amino acid side chain), post-translational modification or other modification in at least one heavy chain, light chain, or combination thereof, that results in a structural change (e.g., a different amino acid side chain, a different post-translational modification or other modification) compared to the parent antibody. The structural change can be determined directly by a variety of methods well known in the art (e.g., LC-MS, direct sequencing) or indirectly via methods such as isoelectric focusing. Such methods are well known to those of skill in the art.

[0023] The term "epitope" as used herein refers to the portion of an antigen that contacts a specific binding domain. Epitopes can be linear or conformational / discontinuous. Conformational or discontinuous epitopes include amino acid residues that are separated by other sequences (i.e., not in a continuous sequence in the primary sequence of the antigen). The residues can be from different regions of the peptide chain, but they are adjacent in the three-dimensional structure of the antigen. In the case of multimeric antigens, conformational or discontinuous epitopes can include residues from different peptide chains. The specific residues included within an epitope can be determined through a three-dimensional structure obtained by a computer modeling program or through methods known in the art, such as X-ray crystallography. As contemplated herein, the term epitope includes post-translational modifications to a polypeptide that can be recognized by an antigen-binding protein or domain, such as the sugar moiety of a glycosylated protein.

[0024] The term "isolated" as used herein means altered or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form, or can exist in a non-native environment (such as, for example, a host cell).

[0025] CD96 (cluster of differentiation 96), also known as TACTILE, is a receptor expressed on T cells and NK cells that shares sequence similarity with CD226 (DNAM01) and is a type 1 transmembrane glycoprotein that belongs to the immunoglobulin superfamily.

[0026] Human CD96 has three isoforms: two membrane (V1; V2) and a soluble form. The longer V1 isoform is a 585 amino acid protein with a MW of 65,634 Da. The shorter isoform V2 (569 aa) has a MW of 63,888 Da. V2 differs from V1 by having a short deletion of the Ig fold in the second domain. The first domain of CD96 contains the epitope(s) required for CD155 binding, while the second domain has been reported to modulate the magnitude / strength of binding. CD96V2 binds CD155 much more strongly than CD96V1 and is also the predominantly expressed form except in acute myeloid leukemia AML (cells). Little is known about the soluble form of CD96 (sCD96). It has been reported that sCD96 has been detected in healthy donor blood (1-3 ng / ml) and higher levels have been detected in Hepatitis B virus (HBV) / cirrhosis patients.

[0027] Based on mRNA analysis of normal human tissues, the highest expression of CD96 (probes that detect both V1 and V2 of CD96) is observed in hematopoietic cells. CD96 expression is also observed in tissues that contain a large number of lymphocytes (e.g., spleen, lung, thyroid, and small intestine). Among hematopoietic cells, CD96 is most abundant in T cells and NK cells, with lower expression in some B cells. Like CD96, TIGIT and CD226 are most abundant in hematopoietic cells and are expressed in both T cells and NK cells. CD226 is also expressed in conventional DC cells. The ligand CD155 shows a broad expression pattern in human normal tissues and is also expressed in DC cells and macrophages (antigen-presenting cells). CD155 is not expressed in T cells or NK cells.

[0028] The binding affinity (KD) of the antigen binding protein-target antigen interaction can be 1 mM or less, 100 nM or less, 10 nM or less, 2 nM or less, or 1 nM or less. Alternatively, the KD can be between 5 and 10 nM; or between 1 and 2 nM. The KD can be between 1 pM and 500 pM; or between 500 pM and 1 nM. For example, certain useful such variants have a binding affinity (KD) that is at least about 40 nM, or at least about 35 nM, or at least about 30 nM, e.g., about 10 pM to about 30 nM.

[0029] The binding affinity of an antigen-binding protein is determined by the association constant (Ka) and dissociation constant (Kd) (KD=Kd / Ka). Binding affinity can be measured by BIACORE™, for example, by capturing the test antibody on a protein A-coated sensor surface and flowing the target antigen over this surface. Alternatively, binding affinity can be measured by FORTEBIO, for example, by capturing the test antibody receptor on a protein A-coated needle and flowing the target antigen over this surface. Alternatively, binding affinity (KD) can be measured by using MSD-SET analysis (MSD solution equilibrium titration), for example, by titrating the test antibody onto a standard binding MSD plate and detecting using an MSD SECTOR IMAGER. MSD-SET determines the solution-phase, equilibrium affinity of antibodies. This known method relies on the detection of free antigen at equilibrium in a titrated series of antibody concentrations.

[0030] The Kd can be 1×10-3 Ms-1 or less, 1×10-4 Ms-1 or less, or 1×10-5 Ms-1 or less. The Kd can be between 1×10-5 Ms-1 and 1×10-4 Ms-1; or between 1×10-4 Ms-1 and 1×10-3 Ms-1. A slow Kd can result in slow dissociation of the antigen-binding protein-target antigen complex and improved neutralization of the target antigen.

[0031] The term "specific antigen binding activity" as used herein refers to antigen binding activity as measured, for example, by surface plasmon resonance (SPR). CD96 specific binding activity can be measured, for example, by BIACORE®, performed in binding mode. TM It can be determined by SPR using an instrument, which is the binding activity divided by the total protein content in the sample.

[0032] The terms "VH" and "VL" are used herein to refer to the heavy and light chain variable regions, respectively, of an antigen binding protein.

[0033] "CDR" is defined as the complementarity determining region amino acid sequence of an antigen-binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDR" as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least one CDR, where at least one CDR is CDRH3. A framework region follows each of these CDR regions. Acceptable framework 1, framework 2, and framework 3 regions of heavy and light chain variable region regions are readily recognized by those skilled in the art. Acceptable heavy chain constant regions (including hinge regions) and light chain constant regions are also readily recognized by those skilled in the art. Acceptable antibody isotypes are also readily recognized by those skilled in the art.

[0034] Throughout this specification, amino acid residues in variable domain sequences and full-length antibody sequences are numbered according to the Kabat numbering convention, as are the terms "CDR", "CDRL1", "CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" used herein.

[0035] It will be apparent to the skilled artisan that there are alternative numbering conventions for the amino acid residues in the variable domain sequences and full-length antibody sequences. There are also alternative numbering conventions for the CDR sequences, such as those described according to the Chothia numbering convention. The structure and protein folding of antibodies may mean that other residues are considered part of the CDR sequences and will be understood as such by the skilled artisan.

[0036] Other numbering conventions for CDR sequences available to those skilled in the art include the "AbM" (University of Bath) and "contact" (University College London) methods. The minimal overlap region using at least two of the Kabat, Chothia, AbM and contact methods can be determined to provide a "minimal binding unit". The minimal binding unit can be a subpart of a CDR.

[0037] Table 1 below presents one definition using each numbering convention for each CDR or binding unit. The Kabat numbering scheme is used in Table 1 to number the variable domain amino acid sequences. It should be noted that some of the CDR definitions may vary depending on the particular publication used.

[0038] [Table 1]

[0039] One embodiment of the disclosure provides a method for the preparation of a CDR comprising the steps of: (a) any one or combination of CDRs selected from (i) CDRH1, CDRH2, CDRH3 from SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, and 94 and / or CDRL1, CDRL2, CDRL3 from SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, and 93; or (ii) a CDR variant of (i) having one, two or three amino acid modifications; or (b) any one or combination of CDRs selected from SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, a VH region comprising a sequence at least 80% identical (or at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical) to a sequence of SEQ ID NO: 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, or 94; and / or a VH region comprising a sequence at least 80% identical (or at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical) to a sequence of SEQ ID NO: 1, 5, 9, 13, 17, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, or 94; 5, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, or 93.

[0040] In another embodiment, the CD96 binding protein comprises: (a) any one or combination of CDRs selected from (i) CDRH1, CDRH2, CDRH3 from SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, and 94, and / or CDRL1, CDRL2, CRDL3 from SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, and 93; or (ii) a CDR variant of (i), comprising one, two or three or (b) a VH region comprising the sequence of SEQ ID NO: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, or 94; and / or a VL region comprising a sequence at least 80% identical (or at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical) to the sequence of SEQ ID NO: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, or 93.

[0041] Another embodiment of the disclosure is a CD96 binding protein according to the previous aspect, comprising a CDRH1 selected from SEQ ID NOs: 105-125; a CDRH2 selected from SEQ ID NOs: 126-146; and / or a CDRH3 selected from SEQ ID NOs: 147-150; a CDRL1 selected from SEQ ID NOs: 97-98; a CDRL2 selected from SEQ ID NOs: 99-100; and / or a CDRL3 selected from SEQ ID NOs: 101-104.

[0042] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding aspects, comprising a CDRH3 that is 100% identical to SEQ ID NO: 147, 148, 149, or 150.

[0043] Another embodiment of the present disclosure is a CDRH1 that is 100% identical to SEQ ID NO: 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, or 125; and / or a CDRH2 that is 100% identical to SEQ ID NO: 147, 148, 149, or 150; a CDRL1 that is 100% identical to SEQ ID NO: 97 or 98148; a CDRL2 that is 100% identical to SEQ ID NO: 99 or 100; and / or a CDRL3 that is 100% identical to SEQ ID NO: 101, 102, 103, or 104.

[0044] Another embodiment of the present disclosure is a CD96 binding protein as described in any one of the preceding aspects, wherein all six CDRs are present in the binding protein.

[0045] Another embodiment of the disclosure is a CD96 binding protein as described in any one of the preceding aspects, comprising a CDRH1 of SEQ ID NO: 115; a CDRH2 of SEQ ID NO: 145; and a CDRH3 of SEQ ID NO: 147; and / or a CDRL1 of SEQ ID NO: 97; a CDRL2 of SEQ ID NO: 99; and a CDRL3 of SEQ ID NO: 101.

[0046] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding aspects, wherein the binding protein comprises a VH region that is 75% identical to SEQ ID NO: 86; and / or a VL region that is 75% identical to SEQ ID NO: 85 (or at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical to these sequences). Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding aspects, wherein the binding protein comprises a VH region that is 100% identical to SEQ ID NO: 86; and / or a VL region that is 100% identical to SEQ ID NO: 85.

[0047] In one embodiment of the disclosure, the invention provides a CD96 binding protein comprising any of the CDRs described herein (alone or in the combination described) and also comprising an Fc region capable of binding to an Fc gamma receptor and / or promoting IFN gamma release. Such an Fc region may be a wild type IgG1 Fc.

[0048] In one embodiment of the disclosure, the invention provides a CD96 binding protein comprising any of the VH regions described herein (alone or in the combinations described) and also comprising an Fc region capable of binding to an Fc gamma receptor and / or promoting IFN gamma release. Such an Fc region may be a wild type IgG1 Fc.

[0049] In one embodiment of the disclosure, the invention provides a CD96 binding protein comprising any of the VL regions described herein (alone or in the combinations described) and also comprising an Fc region capable of binding to an Fc gamma receptor and / or promoting IFN gamma release. Such an Fc region may be a wild type IgG1 Fc.

[0050] Another embodiment of the present disclosure is a CD96 binding protein according to any one of the preceding aspects which is an antibody, wherein the binding protein comprises a (complete) heavy chain 75% identical (or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical) to SEQ ID NO: 165; and / or a (complete) light chain 75% identical (or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical) to SEQ ID NO: 166.

[0051] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding embodiments, wherein the binding protein comprises a VH region that is 100% identical to SEQ ID NO: 86; and / or a VL region that is 100% identical to SEQ ID NO: 85.

[0052] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding embodiments, which is an antibody, wherein the binding protein comprises a (complete) heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO: 165; and / or a (complete) light chain that is 100% identical to the amino acid sequence of SEQ ID NO: 166 (CDRs are underlined in SEQ ID NOs: 165 and 166), or an antibody that binds to CD96, wherein the heavy chain is encoded by the nucleic acid sequence of SEQ ID NO: 167 and / or the light chain is encoded by the nucleic acid sequence of SEQ ID NO: 168.

[0053] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding embodiments, which is an antibody, wherein the binding protein comprises a (complete) heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO: 170; and / or a (complete) light chain that is 100% identical to the amino acid sequence of SEQ ID NO: 169 (CDRs are underlined); or an antibody that binds to CD96, wherein the heavy chain is encoded by the nucleic acid sequence of SEQ ID NO: 172 and / or the light chain is encoded by the nucleic acid sequence of SEQ ID NO: 171.

[0054] Another embodiment of the disclosure is a CD96 binding protein according to any one of the preceding embodiments, which is an antibody, wherein the binding protein comprises a (complete) heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO: 174; and / or a (complete) light chain that is 100% identical to the amino acid sequence of SEQ ID NO: 173 (CDRs are underlined); or an antibody that binds to CD96, wherein the heavy chain is encoded by the nucleic acid sequence of SEQ ID NO: 176 and / or the light chain is encoded by the nucleic acid sequence of SEQ ID NO: 175.

[0055] The invention includes binding proteins that are 100% identical to any of the amino acid sequences described herein, as well as proteins that are variants of the amino acid sequences described herein (e.g., sequences that are at least 75% identical or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5 identical to a sequence herein).

[0056] The invention also includes nucleic acids encoding the binding proteins of the invention (including nucleic acids that are 100% identical to any of the nucleic acid sequences described herein) and nucleic acids that are variants of the sequences described herein (e.g., sequences that are at least 75% identical or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical to a sequence herein).

[0057] The CDRs and variable regions having the amino acid sequences provided in the present application are variable regions that have a binding affinity for CD96 that is equal to or better than that of CD155, and / or that can prevent or displace CD155 from binding to CD96 (examples of binding assays that can be used to determine this are described in Examples 1 and 2 herein). Useful variants of the sequences described herein are variants in which the variable regions have a binding affinity for CD96 that is equal to or better than that of CD155, or that can prevent or displace CD155 from binding to CD96 (examples of binding assays that can be used to determine this are described in Examples 1 and 2 herein). For example, certain useful such variants have a binding affinity (KD) that is at least about 40 nM, or at least about 35 nM, or at least about 30 nM, e.g., about 10 pM to about 30 nM, e.g., when the binding affinity is determined by the MSD-SET assay detailed herein.

[0058] Useful CD96 binding proteins (such as antibodies) according to the invention may comprise such a variable region and an Fc region as described herein, which Fc region is capable of binding to an Fc gamma receptor and / or promoting IFN gamma release. Such an Fc region according to the invention is a wild type IgG1 Fc or a functional variant thereof (e.g., an Fc-neutralized variant capable of binding to an Fc gamma receptor and / or promoting IFN gamma release). Thus, any of the CDRs and / or variable regions of the invention may be combined with an Fc region of the invention, e.g., a wild type IgG1 Fc or a functional variant thereof.

[0059] Another embodiment of the present disclosure is a CD96 binding protein according to any one of the preceding aspects, wherein the binding protein comprises a synthetic polypeptide, a humanized sequence, or a chimeric sequence.

[0060] As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or change the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the antibody or antibody fragment of the invention by standard techniques known in the art (e.g., site-directed mutagenesis and PCR-mediated mutagenesis). Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0061] The term "domain" refers to a folded protein structure that retains its tertiary structure independently of the rest of the protein. Generally, domains are responsible for distinct functional properties of the protein and often can be added, removed, or transferred to other proteins without loss of function of the remainder of the protein and / or the domain.

[0062] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in either single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids that contain known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0063] One embodiment of the present disclosure is a nucleic acid sequence encoding a CD96 binding protein described in any one of the preceding embodiments.

[0064] A further embodiment of the disclosure is a nucleic acid sequence as described in the preceding embodiments, wherein the sequence comprises SEQ ID NO: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, or 96 encoding a heavy chain; and / or SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, 79, 83, 87, 91, or 95 encoding a light chain. Another embodiment of the disclosure is an expression vector comprising a nucleic acid as described in any of the preceding embodiments.

[0065] The compositions described herein can be produced by any number of conventional techniques. For example, the compositions can be expressed in and purified from a recombinant expression system. In one embodiment, the compositions are produced by a method of culturing a host cell under conditions suitable for expression of a CD96 binding protein described in any of the preceding embodiments, which is expressed and optionally purified, and optionally formulated into a pharmaceutical composition.

[0066] A number of different expression systems and purification regimes can be used to produce the compositions. Generally, the host cell is transformed with a recombinant expression vector encoding the antibody. A wide range of host cells can be used, including eukaryotic cell lines of mammalian origin (e.g., CHO, Perc6, HEK293, HeLa, NS0). Suitable host cells include mammalian cells such as CHO (e.g., CHOK1 and CHO-DG44).

[0067] The host cell may be an isolated host cell. The host cell is not normally part of a multicellular organism (e.g., a plant or an animal). The host cell may be a non-human host cell.

[0068] Appropriate cloning and expression vectors and cloning methods for use with eukaryotic or mammalian cell hosts are known in the art.

[0069] The cells can be cultured under conditions that promote expression of the antibody. For example, a production bioreactor is used to culture the cells. The volume of the production bioreactor can be (i) about 20,000 liters, about 10,000 liters; about 5,000 liters; about 2,000 liters; about 1,000 liters; or about 500 liters; or (ii) 500 to 20,000 liters; 500 to 10,000 liters; 500 to 5,000 liters; 1,000 to 10,000 liters, or 2,000 to 10,000 liters. For example, the cells can be cultured in the production bioreactor at a pH of about 6.75 to pH 7.00. Alternatively, the cells can be cultured in the production bioreactor for about 12 to about 18 days. Alternatively, the cells can be cultured in the production bioreactor at a pH of about 6.75 to about 7.00 for about 12 to about 18 days. This culturing step may help to control, e.g. reduce, the levels of deamidated antibody variants.

[0070] The composition may be harvested and purified by conventional protein purification procedures. For example, the composition may be harvested directly from the culture medium. Harvesting of the cell culture medium may be via clarification, for example, by centrifugation and / or depth filtration. After harvesting the composition, purification is performed to ensure appropriate purity.

[0071] A further embodiment of the present disclosure is a recombinant host cell comprising a nucleic acid sequence or expression vector as described in any of the preceding embodiments. Another embodiment of the present disclosure is a method for producing a CD96 binding protein comprising culturing a host cell as described in the preceding embodiments under conditions suitable for expression of said nucleic acid sequence or vector, thereby producing a polypeptide comprising the CD96 binding protein. A further embodiment of the present disclosure is a CD96 binding protein produced by the production method as described in the preceding embodiments. Another embodiment of the present disclosure is a cell line engineered to express a CD96 binding protein as described in any one of the preceding embodiments.

[0072] The "percent identity" between a query nucleic acid sequence and a subject nucleic acid sequence is the "identity" value expressed as a percentage, which is calculated by the BLASTN algorithm when the subject nucleic acid sequence has 100% query coverage with the query nucleic acid sequence after pairwise BLASTN alignment is performed. Such pairwise BLASTN alignment between the query nucleic acid sequence and the subject nucleic acid sequence is performed using the default settings of the BLASTN algorithm available at the National Center for Biotechnology Institute website, with the filter for low complexity regions turned off. Importantly, the query nucleic acid sequence may be described by a nucleic acid sequence identified in one or more claims herein.

[0073] The "percent identity" between a query amino acid sequence and a subject amino acid sequence is the "identity" value expressed as a percentage, which is calculated by the BLASTP algorithm when the subject amino acid sequence has 100% query coverage with the query amino acid sequence after pairwise BLASTP alignment is performed. Such pairwise BLASTP alignment between the query amino acid sequence and the subject amino acid sequence is performed using the default settings of the BLASTP algorithm available on the National Center for Biotechnology Institute website, with the filter for low complexity regions turned off. Importantly, the query amino acid sequence may be described by an amino acid sequence specified in one or more claims herein.

[0074] The query sequence may be 100% identical to the subject sequence, or it may contain up to a certain integer number of amino acid or nucleotide alterations compared to the subject sequence such that the identity percentage is less than 100%. For example, the query sequence is at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical to the subject sequence. Such alterations include at least one amino acid deletion, substitution (including conservative and non-conservative substitutions), or insertion, which may occur at the amino- or carboxy-terminal positions of the query sequence, or anywhere between these terminal positions, either individually among the amino acids or nucleotides in the query sequence, or interspersed in one or more contiguous groups within the query sequence.

[0075] As used herein, "sequence identity" is the degree of relatedness between two or more amino acid sequences or between two or more nucleic acid sequences, as determined by comparing the sequences. Comparison of sequences and determination of sequence identity can be accomplished using a mathematical algorithm; those skilled in the art are aware of computer programs available for aligning two sequences and determining the percent identity between them. Those skilled in the art will understand that different algorithms may produce slightly different results.

[0076] The term "specifically binds" and grammatical variations thereof, as used herein with respect to an antibody, refers to an antibody or antibody fragment that recognizes and binds to a specific antigen but does not substantially recognize or bind other molecules in a sample. For example, an antibody that specifically binds to an antigen from one species may also bind to that antigen from one or more species. However, such cross-species reactivity does not in itself change the classification of the antibody as specific. In another example, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross-reactivity does not in itself change the classification of the antibody as specific. In some examples, the terms "specific binding" or "specifically binding" may be used with respect to the interaction of an antibody, protein, or peptide with a second chemical species, meaning that the interaction is dependent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure, not proteins in general. If an antibody is specific for epitope "A", then in a reaction containing labeled "A" and the antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of labeled A bound to the antibody.

[0077] As used herein, the term "pharmaceutical composition" means a composition suitable for administration to a patient.

[0078] The pharmaceutical compositions described herein can include purified preparations of the CD96 binding proteins described herein.

[0079] For example, a pharmaceutical preparation can include a purified preparation of a CD96 binding protein described herein in combination with a pharma- ceutically acceptable carrier.

[0080] Typically, such pharmaceutical compositions will include a pharma- ceutically acceptable carrier as known and required by accepted pharmaceutical practice, examples of such carriers include sterile carriers such as saline, Ringer's solution, or dextrose solution, optionally buffered to a pH within the range of 5 to 8 with an appropriate buffer.

[0081] The pharmaceutical composition may be administered by injection or infusion (e.g., intravenously, intraperitoneally, intradermally, subcutaneously, intramuscularly, or intraportally). Such compositions are preferably free of visible particulate matter. The pharmaceutical composition may comprise between 1 mg and 10 g of antigen binding protein, for example between 5 Mg and 1 g of antigen binding protein. Alternatively, the composition may comprise between 5 Mg and 500 mg of antigen binding protein, for example between 5 Mg and 50 mg.

[0082] Methods for preparing such pharmaceutical compositions are well known to those of skill in the art. The pharmaceutical composition may contain 1 mg to 10 g of antigen binding protein in a unit dosage form, optionally with instructions for use. The pharmaceutical composition may be lyophilized (freeze-dried) for reconstitution prior to administration according to methods well known or apparent to those of skill in the art. If the antibody has an IgG1 isotype, a citrate salt (e.g., sodium citrate) or a copper chelator such as EDTA or histidine may be added to the pharmaceutical composition to reduce the extent of copper-mediated degradation of antibodies of this isotype. The pharmaceutical composition may also include a solubilizer such as arginine, a surfactant / anti-agglomerating agent such as polysorbate 80, and an inert gas such as nitrogen to replace vial headspace oxygen.

[0083] One embodiment of the present disclosure is a pharmaceutical composition comprising a CD96 binding protein as described in any of the preceding embodiments and a pharma- ceutical acceptable excipient. A further embodiment of the present disclosure is a pharmaceutical composition comprising a therapeutically effective amount of a CD96 binding protein as described in any one of the preceding embodiments.

[0084] The term "anti-tumor effect" as used herein refers to a biological effect that may be manifested by a decrease in tumor growth rate, a decrease in tumor volume, a decrease in tumor cell number, a decrease in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with a cancerous condition. An "anti-tumor effect" may also be manifested by the ability of the peptides, polynucleotides, cells, and antibodies of the invention to prevent the development of tumors in the first place.

[0085] As used herein, the terms "cancer", "neoplasm" and "tumor" are used interchangeably and are used in either the singular or plural form to refer to cells that have undergone malignant transformation and are therefore pathological to the host organism. Illustrative examples of cells that may be targeted by the contemplated compositions and methods in certain embodiments include, but are not limited to, the following cancers: synovial sarcoma, non-small cell lung cancer (NSCLC), myxoid round cell liposarcoma (MRCLS), and multiple myeloma (MM). Primary cancer cells can be easily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of cancer cells used herein includes not only primary cancer cells, but also any cells derived from a cancer cell ancestor. This includes metastasized cancer cells, as well as in vitro cultures and cell lines derived from cancer cells. When referring to types of cancer that usually present as solid tumors, a "clinically detectable" tumor is one that can be detected based on the tumor mass, for example, by procedures such as computed tomography (CT) scan, magnetic resonance imaging (MRI), X-ray, ultrasound, or palpation during physical examination, and / or by the expression of one or more cancer-specific antigens in samples available from the patient. The tumor can be a hematopoietic (or hematologic (hematological) (blood-related) cancer, such as a cancer derived from blood cells or immune cells, which are also referred to as "liquid tumors". Specific examples of clinical conditions based on blood tumors include leukemias such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia; plasma cell malignancies such as multiple myeloma, MGUS, and Waldenstrom's macroglobulinemia; lymphomas such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, etc.

[0086] The cancer may be any cancer in which there is an abnormal number of blast cells or unwanted cell proliferation, or is diagnosed as a blood cancer, including both lymphoid and myeloid malignancies.Myeloid malignancies include, but are not limited to, acute myeloid leukemia (or myelocytic or myelogenous or myeloblastic) leukemia (undifferentiated or differentiated), acute promyelocytic (or promyelocytic or promyelocytic or promyeloblastic) leukemia, acute myelomonocytic (or myelomonoblastic) leukemia, acute monocytic (or monoblastic) leukemia, erythroleukemia, and megakaryocytic (or megakaryoblastic) leukemia.These leukemias may be collectively referred to as acute myeloid (or myelocytic or myeloid) leukemia (AML). Myeloid malignancies also include myeloproliferative disorders (MPDs), including but not limited to chronic myelogenous (or myeloid) leukemia (CML), chronic myelomonocytic leukemia (CMML), essential thrombocythemia (or thrombocytosis), and polycythemia vera (PCV). Myeloid malignancies can also include myelodysplasia (or myelodysplastic syndromes or MDS), which can be referred to as refractory anemia (RA), refractory anemia with excess blasts (RAEB), and refractory anemia with excess blasts in transformation (RAEBT); and myelofibrosis (MFS), with or without myeloid metaplasia of unknown etiology.

[0087] Hematopoietic cancers also include lymphoid malignancies that may affect lymph nodes, spleen, bone marrow, peripheral blood, and / or extranodal sites. Lymphoid cancers include B-cell malignancies, including but not limited to B-cell non-Hodgkin's lymphoma (B-NHL). B-NHL may be indolent (or low grade), intermediate grade (or aggressive), or high grade (highly aggressive). Indolent B-cell lymphomas include follicular lymphoma (FL); small lymphocytic lymphoma (SLL); marginal zone lymphoma (MZL), including nodal MZL, extranodal MZL, splenic MZL, and splenic MZL with villous lymphocytes; lymphoplasmacytic lymphoma (LPL); and mucosa-associated lymphoid tissue (MALT or extranodal marginal zone) lymphoma. Intermediate-grade B-NHL includes mantle cell lymphoma (MCL) with or without leukemic involvement, diffuse large cell lymphoma (DLBCL), follicular large cell (or grade 3 or grade 3B) lymphoma, and primary mediastinal lymphoma (PML). High-grade B-NHL includes Burkitt lymphoma (BL), Burkitt-like lymphoma, small noncleaved cell lymphoma (SNCCL), and lymphoblastic lymphoma. Other B-NHLs include immunoblastic lymphoma (or immunocytoma), primary effusion lymphoma, HIV-associated (or AIDS-associated) lymphoma, and post-transplant lymphoproliferative disorder (PTLD) or lymphoma. B-cell malignancies also include, but are not limited to, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), Waldenstrom's macroglobulinemia (WM), hairy cell leukemia (HCL), large granular lymphocytic (LGL) leukemia, acute lymphocytic leukemia (or lymphocytic or lymphoblastic leukemia), and Castleman's disease. NHL may also include T-cell non-Hodgkin's lymphoma (T-NHL), including, but not limited to, T-cell non-Hodgkin's lymphoma not otherwise specified (NOS), peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoid disorder (AILD), nasal natural killer (NK) cell / T-cell lymphoma, gamma / delta lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, and Sézary syndrome.

[0088] Hematopoietic cancers also include Hodgkin lymphomas (or diseases), including classical Hodgkin lymphoma, nodular sclerosing Hodgkin lymphoma, mixed cellularity Hodgkin lymphoma, lymphocyte predominant (LP) Hodgkin lymphoma, nodular LP Hodgkin lymphoma, and lymphocyte depleted Hodgkin lymphoma. Hematopoietic cancers also include plasma cell disorders or cancers, such as multiple myeloma (MM), including smoldering MM, monoclonal gammopathy of undetermined (or unknown or unclear) significance (MGUS), plasmacytoma (bone, extramedullary), lymphoplasmacytic lymphoma (LPL), Waldenstrom macroglobulinemia, plasma cell leukemia, and primary amyloidosis (AL). Hematopoietic cancers may also include other cancers of additional hematopoietic cells, including polymorphonuclear leukocytes (or neutrophils), basophils, eosinophils, dendritic cells, platelets, erythrocytes, and natural killer cells. Tissues containing hematopoietic cells, referred to herein as "hematopoietic cell tissues," include bone marrow; peripheral blood; thymus; and peripheral lymphoid tissues such as the spleen, lymph nodes, lymphoid tissues associated with mucosa (e.g., gut-associated lymphoid tissue), tonsils, Peyer's patches, and appendix, as well as lymphoid tissues associated with other mucosa (e.g., the bronchial lining).

[0089] In one embodiment, cancers that may be treated with the binding proteins of the invention may include solid tumors (e.g., recurrent, metastatic, or progressive solid tumors). Examples of such solid tumors include ovarian, lung (e.g., NSCLC), gastric, bladder, colorectal, liver (e.g., HCC), renal (e.g., RCC), and head and neck squamous cell carcinoma (HNSCC).

[0090] The term "therapeutic" as used herein means treatment and / or prophylaxis. A therapeutic effect is achieved by suppression, amelioration, or eradication of a disease state.

[0091] As used herein, a "therapeutically effective amount" or "effective amount" refers to an amount that elicits the biological or medical response or provides a therapeutic or prophylactic benefit in a tissue, system, or subject that is being sought by a researcher, veterinarian, physician, or other clinician. Therapeutically effective amounts and treatment regimens are generally determined empirically and may depend on factors such as the age, weight, and health of the patient and the disease or disorder being treated. Such factors are within the purview of the attending physician.

[0092] As used herein, the term "treating" and its grammatical variations refer to therapeutic treatment. With respect to a particular condition, treating means: (1) improving or preventing the condition of one or more biological manifestations of the condition; (2) (a) interfering with one or more points in the biological cascade that leads to or causes the condition, or (b) one or more biological manifestations of the condition; (3) alleviating one or more symptoms, effects, or side effects associated with the condition or its treatment; (4) slowing the progression of the condition or one or more biological manifestations of the condition; and / or (5) curing the condition or one or more biological manifestations of the condition by eliminating or reducing to undetectable levels without further treatment for a period considered to be in a state of remission for the manifestation. Those skilled in the art will understand the period considered to be in remission for a particular disease or condition. Prophylactic treatment is also contemplated thereby. Those skilled in the art will understand that "prevention" is not an absolute term. In medicine, "prevention" is understood to refer to the prophylactic administration of a drug to substantially reduce the likelihood or severity of a condition or its biological manifestations, or to delay the onset of such a condition or its biological manifestations. Prophylactic treatment is appropriate, for example, when a subject is considered to be at high risk of developing cancer, for example, when the subject has a strong family history of cancer, or when the subject has been exposed to a carcinogen.

[0093] The terms "individual," "subject," and "patient" are used interchangeably herein. In one embodiment, the subject is a mammal, such as a primate, e.g., a marmoset or monkey, or a human. In a further embodiment, the subject is a human.

[0094] The dosage of the antigen-binding protein administered to a subject is generally 1 μg / kg to 150 mg / kg, 0.1 mg / kg to 100 mg / kg, 0.5 mg / kg to 50 mg / kg, 1 to 25 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or 1 to 10 mg / kg of the subject's body weight. For example, the dosage can be 10 mg / kg, 30 mg / kg, or 60 mg / kg. The dosage can also be 10 mg / kg to 110 mg / mg, 15 mg / kg to 25 mg / kg, or 15 mg / kg to 100 mg / kg. The antigen-binding protein can be administered, for example, parenterally, subcutaneously, intravenously, or intramuscularly. The dosage can also be administered on a per subject basis, such as about 20 mg per subject to about 750 mg per subject, about 75 mg per subject to about 750 mg per subject, about 20 mg per subject to about 200 mg per subject, etc. The dose can be any individual subrange within these dose ranges. For example, the dose can also be administered subcutaneously on a subject basis, such as about 100 mg / subject (e.g., once every 4 weeks), or 300 mg / subject (or other doses administered can be administered subcutaneously if approximately the same or comparable bioavailability is achieved as with intravenous administration, e.g., three 100 mg doses per subject to achieve a total subcutaneous dose of 300 mg per subject).

[0095] Ranges provided herein, of any kind, include all values ​​within the particular range recited, as well as the values ​​at the end points of the particular range.

[0096] If desired, the effective daily dose of an antibody or antigen binding protein of the disclosure (e.g., as a pharmaceutical composition) may be administered as two, three, four, five, six or more doses administered separately at appropriate intervals throughout the day, optionally in unit dosage forms.

[0097] Administration of the dose may be by slow continuous infusion over a period of 2 to 24 hours, such as 2 to 12 hours, or 2 to 6 hours. Such administration may result in reduced side effects.

[0098] The administration of the dose can be repeated one or more times as needed, for example, three times a day, once daily, once every two days, once weekly, once every 14 days, once monthly, once every three months, once every four months, once every six months, or once every twelve months. The antigen-binding protein may be administered by maintenance therapy, for example, once weekly for a period of six months or more. The antigen-binding protein may be administered by intermittent therapy, for example, for a period of three to six months, then not administered for three to six months, after which the antigen-binding protein is administered again for three to six months, and so forth.

[0099] For example, the dose may be administered subcutaneously once every 14 or 28 days in the form of multiple doses on each day of administration. In one embodiment, the dosage of the composition is 100 mg once every 4 weeks (28 days).

[0100] The antigen binding protein can be administered to a subject in such a way as to target the treatment to a specific site.

[0101] The CD96 binding proteins in the methods of the present disclosure may be used in combination or co-administered with one or more other therapeutically active agents, such as antibodies, small molecule inhibitors, or may be used in combination with cell therapy. As used herein, the term "co-administration" refers to either simultaneous administration or separate sequential administration in any manner of the CD96 binding proteins described herein with additional active agent(s) known to be useful in the treatment of cancer, including chemotherapy and radiation therapy. As used herein, the term additional active agent(s) includes any compound or therapeutic agent known to exhibit advantageous properties when administered to a patient in need of cancer treatment. Preferably, if the administration is not simultaneous, the compounds are administered in close temporal proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, for example, one compound may be administered by injection and another compound may be administered orally.

[0102] Typically, any anti-neoplastic agent that has activity against the susceptible tumor being treated may be co-administered in the treatment of cancer in the present invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology by VT Devita, TS Lawrence, and SA Rosenberg (editors), 10th edition (December 5, 2014), Lippincott Williams & Wilkins Publishers. A person skilled in the art will be able to identify which combinations of agents are useful based on the specific characteristics of the drugs and cancer involved. Exemplary anti-neoplastic agents useful in the present invention include, but are not limited to, anti-microtubule or anti-mitotic agents; platinum coordination complexes; alkylating agents; antibiotics; topoisomerase I inhibitors; topoisomerase II inhibitors; antimetabolites; hormones and hormone analogs; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; cell cycle signal transduction inhibitors; proteasome inhibitors; heat shock protein inhibitors; inhibitors of cancer metabolism; and cancer gene therapy agents.

[0103] Examples of additional active ingredients for use in combination with or co-administration with the CD96 binding proteins of the present disclosure are anti-neoplastic agents. Examples of anti-neoplastic agents include, but are not limited to, chemotherapeutic agents, immunoregulatory agents, immunomodulators, and immunostimulatory adjuvants.

[0104] The CD96 binding protein of the present disclosure may also be used in combination with anti-TIGIT antibody. Such combination can further enhance CD155 / CD226 activation. The combination with anti-TIGIT antibody can be used to treat solid tumors such as renal tumors, e.g. renal cell carcinoma (RCC). An example of such an anti-TIGIT antibody is tiragolumab.

[0105] Anti-microtubule or anti-mitotic agents are phase-specific agents active against the microtubules of tumor cells during the M or mitosis phase of the cell cycle. Examples of anti-microtubule agents include, but are not limited to, diterpenoids and vinca alkaloids.

[0106] Platinum coordination complexes are non-phase specific anticancer drugs that interact with DNA. Platinum complexes enter tumor cells, undergo aquation, and form intrastrand and interstrand crosslinks with DNA, causing adverse biological effects on tumors. Examples of platinum coordination complexes include, but are not limited to, cisplatin and carboplatin.

[0107] Alkylating agents are non-stage anti-cancer specific agents and strong electrophiles. Typically, alkylating agents form covalent bonds with DNA through nucleophilic moieties of the DNA molecule, such as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole groups, by alkylation. Such alkylation disrupts nucleic acid function, resulting in cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards, such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates, such as busulfan; nitrosoureas, such as carmustine; and triazenes, such as dacarbazine.

[0108] Antibiotic antineoplastic agents are non-phase specific agents that bind or intercalate with DNA. This action disrupts the normal function of nucleic acids, resulting in cell death. Examples of antibiotic antineoplastic agents include, but are not limited to, actinomycins such as dactinomycin; anthracyclines such as daunorubicin and doxorubicin; and bleomycin.

[0109] Topoisomerase I inhibitors include, but are not limited to, camptothecin, whose cytotoxic activity is believed to be related to its Topoisomerase I inhibitory activity.

[0110] Topoisomerase II inhibitors include, but are not limited to, epipodophyllotoxins. Epipodophyllotoxins are phase-specific antineoplastic agents derived from mandrake plants. Epipodophyllotoxins typically affect cells in the S and G2 phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA, causing DNA strand breaks. Strand breaks accumulate and cell death follows. Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.

[0111] Antimetabolite anti-neoplastic agents are phase-specific anti-neoplastic agents that act at the S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis, thereby limiting DNA synthesis. As a result, S phase does not progress and cell death ensues. Examples of antimetabolite anti-neoplastic agents include, but are not limited to, fluorouracil, methotrexate, cytarabine, mercaptopurine, thioguanine, and gemcitabine.

[0112] Hormones and hormone analogs are compounds useful for treating cancers where there is a relationship between a hormone(s) and the growth and / or lack of growth of the cancer. Examples of hormones and hormone analogs useful for cancer treatment include, but are not limited to, corticosteroids, such as prednisone and prednisolone; aminoglutethimide and other aromatase inhibitors, such as anastrozole, letrazole, botrazol and exemestane; progestrins, such as megestrol acetate; estrogens, androgens and antiandrogens, such as flutamide, nilutamide, bicalutamide, cyproterone acetate and 5α-reductase inhibitors, such as ... anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, and selective estrogen receptor modulators (SERMS); and gonadotropin releasing hormone (GnRH) and its analogs (which stimulate the release of luteinizing hormone (LH) and / or follicle stimulating hormone (FSH)), LHRH agonists, and antagonists such as goserelin acetate and leuprolide.

[0113] Signal transduction pathway inhibitors are inhibitors that block or inhibit chemical processes that cause intracellular changes. As used herein, this change is cell proliferation or differentiation. Signal transduction inhibitors useful in the present invention include, but are not limited to, receptor tyrosine kinases, non-receptor tyrosine kinases, SH2 / SH3 domain blockers, serine / threonine kinases, phosphatidylinositol-3 kinases, myoinositol signaling, and Ras oncogene inhibitors.

[0114] Several protein tyrosine kinases catalyze the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth. Such protein tyrosine kinases can be broadly classified as receptor or non-receptor kinases.

[0115] Receptor tyrosine kinases are transmembrane proteins that have an extracellular ligand-binding domain, a transmembrane domain and a tyrosine kinase domain. Receptor tyrosine kinases are involved in the regulation of cell growth and are generally called growth factor receptors. Inappropriate or uncontrolled activation of many of these kinases, for example by overexpression or mutation, i.e., abnormal kinase growth factor receptor activity, has been shown to result in uncontrolled cell growth. Thus, the abnormal activity of such kinases is associated with malignant tissue growth. As a result, inhibitors of such kinases can provide a method of cancer treatment. Growth factor receptors include, for example, epidermal growth factor receptor (EGFr), platelet-derived growth factor receptor (PDGFr), erbB2, erbB4, vascular endothelial growth factor receptor (VEGFR), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor-I (IGFI) receptor, macrophage colony-stimulating factor (Cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptor, Trk receptors (TrkA, TrkB, and TrkC), ephrin (eph) receptors, and the RET proto-oncogene. Several inhibitors of growth receptors are in development, including ligand antagonists, antibodies, tyrosine kinase inhibitors, and antisense oligonucleotides. Growth factor receptors and agents that inhibit growth factor receptor function are described, for example, in Kath JC, Exp. Opin. Ther. Patents, 10(6):803-818 (2000); Shawver LK, et al., Drug Discov. Today, 2(2): 50-63 (1997); and Lofts, FJ and Gullick WJ, "Growth factor receptors as targets." in New Molecular Targets for Cancer Chemotherapy, Kerr DJ and Workman P. (editors), (June 27, 1994), CRC Press. Non-limiting examples of growth factor receptor inhibitors include pazopanib and sorafenib.

[0116] Tyrosine kinases that are not growth factor receptor kinases are called non-receptor tyrosine kinases. Non-receptor tyrosine kinases that are targets or potential targets of anti-cancer drugs and are useful in the present invention include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (focal adhesion kinase), Bruton's tyrosine kinase, and Bcr-Abl. Such non-receptor kinases and drugs that inhibit non-receptor tyrosine kinase function are described in Sinha S. and Corey SJ, J. Hematother. Stem Cell Res., 8(5): 465-480 (2004) and Bolen, JB, Brugge, JS, Annu. Rev. Immunol., 15: 371-404 (1997).

[0117] SH2 / SH3 domain blockers are drugs that disrupt SH2 or SH3 domain binding in various enzymes or adaptor proteins, including PI3-Kp85 subunit, Src family kinases, adaptor molecules (Shc, Crk, Nck, Grb2) and Ras-GAP. SH2 / SH3 domains as targets for anticancer drugs are discussed in Smithgall TE, J. Pharmacol. Toxicol. Methods, 34(3): 125-32 (1995).

[0118] Inhibitors of serine / threonine kinases include MAP kinase cascade blockers, including but not limited to blockers of Raf kinase (rafk), mitogen or extracellular regulated kinases (MEKs), and extracellular regulated kinases (ERKs); protein kinase C family member blockers, including blockers of PKCs (alpha, beta, gamma, epsilon, mu, lambda, iota, zeta); IkB kinase (IKKa, IKKb); PKB family kinases; AKT kinase family members; TGF beta receptor kinase; and mammalian target of rapamycin (mTOR) inhibitors, including but not limited to rapamycin (FK506) and rapalogues, RAD001 or everolimus (AFINITOR™), CCI-779 or temsirolimus, AP23573, AZD8055, WYE-354, WYE-600, WYE-687, and Pp121. Examples of inhibitors of serine / threonine kinases include, but are not limited to, trametinib, dabrafenib, and the Akt inhibitors afuresertib and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide.

[0119] Inhibitors of phosphatidylinositol 3-kinase family members, including blockers of PI3-kinase, ATM, DNA-PK, and Ku, are also useful in the present invention. For such kinases, see Abraham RT, Curr. Opin. Immunol., 8(3): 412-418 (1996); Canman CE, and Lim DS, Oncogene, 17(25): 3301-3308 (1998); Jackson SP, Int. J. Biochem. Cell Biol., 29(7): 935-938 (1997); and Zhong H., et al., Cancer Res., 60(6): 1541-1545 (2000).

[0120] Myo-inositol signaling inhibitors, such as phospholipase C blockers and myo-inositol analogs, are also useful in the present invention. Such signaling inhibitors are described in Powis G., and Kozikowski A., "Inhibitors of Myo-Inositol Signaling." in New Molecular Targets for Cancer Chemotherapy, Kerr DJ and Workman P. (editors), (June 27, 1994), CRC Press.

[0121] Another group of signal transduction pathway inhibitors are inhibitors of the Ras oncogene. Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyltransferase and CAAX protease, as well as antisense oligonucleotides, ribozymes and other immunotherapies. Such inhibitors have been shown to block ras activation in cells containing wild-type mutant ras, thereby acting as antiproliferative agents. Ras oncogene inhibition is discussed in Scharovsky OG, et al., J. Biomed. Sci., 7(4): 292-298 (2000); Ashby MN, Curr. Opin. Lipidol., 9(2): 99-102 (1998); and Bennett CF and Cowsert LM, Biochem. Biophys. Acta., 1489(1): 19-30 (1999).

[0122] Antagonists for receptor kinase ligand binding can also act as signal transduction inhibitors. This group of signal transduction pathway inhibitors includes the use of humanized antibodies or other antagonists against the extracellular ligand binding domain of receptor tyrosine kinases. Examples of antibodies or other antagonists for receptor kinase ligand binding include, but are not limited to: cetuximab (ERBITUX™), trastuzumab (HERCEPTIN™); trastuzumab emtansine (KADCYLA™); pertuzumab (PERJETA™); ErbB inhibitors including lapatinib, erlotinib, and gefitinib; and 2C3 VEGFR2 specific antibody (see Brekken RA, et al., Cancer Res., 60(18): 5117-5124 (2000)).

[0123] Non-receptor kinase angiogenesis inhibitors may also be used in the present invention. Inhibitors of angiogenesis-related VEGFR and TIE2 have been discussed above with respect to signal transduction inhibitors (both receptors are receptor tyrosine kinases). Angiogenesis is generally related to erbB2 / EGFR signal transduction, as inhibitors of erbB2 and EGFR have been shown to inhibit angiogenesis, primarily VEGF expression. Thus, non-receptor tyrosine kinase inhibitors may be used in combination with the EGFR / erbB2 inhibitors of the present invention. For example, anti-VEGF antibodies that do not recognize VEGFR (receptor tyrosine kinase) but bind to the ligand; small molecule inhibitors of integrin (alpha beta 3) that inhibit angiogenesis; endostatin and angiostatin (non-RTK) may also prove useful in combination with the disclosed compounds. (See Bruns CJ, et al., Cancer Res., 60(11): 2926-2935 (2000); Schreiber AB, et al., Science, 232(4755): 1250-1253 (1986); Yen L., et al., Oncogene, 19(31): 3460-3469 (2000)).

[0124] Agents used in immunotherapy regimens may also be useful in combination with the present invention. There are many immunological strategies to generate an immune response against erbB2 or EGFR. These strategies are generally in the area of ​​tumor vaccination. The efficacy of immunological approaches can be greatly enhanced by combined inhibition of the erbB2 / EGFR signaling pathway using small molecule inhibitors. A review of immunological / tumor vaccine approaches against erbB2 / EGFR can be found in Reilly RT, et al., Cancer Res., 60(13): 3569-3576 (2000); and Chen Y., et al., Cancer Res., 58(9): 1965-1971 (1998).

[0125] Agents used in pro-apoptotic regimens (e.g., Bcl-2 antisense oligonucleotides) can also be used in the combination of the present invention. Members of the Bcl-2 family of proteins block apoptosis. Thus, upregulation of Bcl-2 has been associated with chemotherapy resistance. Studies have shown that epidermal growth factor (EGF) stimulates anti-apoptotic members of the Bcl-2 family (i.e., Mcl-1). Thus, strategies designed to downregulate the expression of Bcl-2 in tumors have demonstrated clinical benefit. Such pro-apoptotic strategies using antisense oligonucleotide strategies for Bcl-2 are discussed in Waters JS, et al., J. Clin. Oncol., 18(9): 1812-1823 (2000); and Kitada S., et al., Antisense Res. Dev., 4(2): 71-79 (1994).

[0126] Cell cycle signaling inhibitors inhibit molecules involved in the control of the cell cycle. A family of protein kinases called cyclin-dependent kinases (CDKs) and their interaction with a family of proteins called cyclins control the progression of the eukaryotic cell cycle. The coordinated activation and inactivation of different cyclin / CDK complexes is necessary for normal progression through the cell cycle. Several inhibitors of cell cycle signaling are under development. For example, examples of cyclin-dependent kinases (including CDK2, CDK4, and CDK6) and their inhibitors are described, for example, in Rosania GR, and Chang YT, Exp. Opin. Ther. Patents, 10(2): 215-230 (2000). Furthermore, p21WAF1 / CIP1 has been described as a potent and universal inhibitor of cyclin-dependent kinases (Cdks) (Ball KL, Prog. Cell Cycle Res., 3: 125-134 (1997)). Compounds known to induce the expression of p21WAF1 / CIP1 are said to be involved in the inhibition of cell proliferation and have tumor suppressor activity (Richon VM, et al., Proc. Natl. Acad. Sci. USA, 97(18): 10014-10019 (2000)), and are included as cell cycle signaling inhibitors. Histone deacetylase (HDAC) inhibitors are involved in the transcriptional activation of p21WAF1 / CIP1 (Vigushin DM, and Coombes RC, Anticancer Drugs, 13(1): 1-13 (2002)), and are suitable cell cycle signaling inhibitors for use in combination herein. Examples of such HDAC inhibitors include, but are not limited to, vorinostat, romidepsin, panobinostat, valproic acid, and mocetinostat.

[0127] Proteasome inhibitors are drugs that block the action of proteasomes, which are cellular complexes that break down proteins such as p53 protein.Some proteasome inhibitors are commercially available or are being studied for the treatment of cancer.Proteasome inhibitors suitable for use in combination herein include, but are not limited to, bortezomib, disulfiram, epigallocatechin gallate, salinosporamide A, and carfilzomib.

[0128] Heat shock protein of 70 kilodaltons (Hsp70) and heat shock protein of 90 kilodaltons (Hsp90) are a family of ubiquitously expressed heat shock proteins. Hsp70 and Hsp90 are overexpressed in certain cancer types. Several Hsp70 and Hsp90 inhibitors have been investigated in the treatment of cancer. Examples of Hsp70 and Hsp90 inhibitors for use in combination herein include, but are not limited to, tanespimycin and radicicol.

[0129] Many tumor cells exhibit a metabolism that differs significantly from normal tissues. For example, the rate of glycolysis, the metabolic process that converts glucose into pyruvate, is increased, and the pyruvate produced is reduced to lactate rather than being further oxidized in mitochondria via the tricarboxylic acid (TCA) cycle. This effect, which is often seen even under aerobic conditions, is known as the Warburg effect.

[0130] Lactate dehydrogenase A (LDH-A), an isoform of lactate dehydrogenase expressed in muscle cells, plays a vital role in tumor cell metabolism by reducing pyruvate to lactate, which can then be transported out of the cell. This enzyme has been shown to be upregulated in many tumor types. Alterations in glucose metabolism, described in the Warburg effect, are important for cancer cell growth and proliferation, and knockdown of LDH-A using RNA-i has been shown to result in reduced cell proliferation and tumor growth in xenograft models (Tennant DA, et al., Nat. Rev. Cancer, 10(4): 267-277 (2010); Fantin VR, et al., Cancer Cell, 9(6): 425-434 (2006)).

[0131] High levels of fatty acid synthase (FAS) have been found in cancer precursor lesions. Pharmacological inhibition of FAS affects the expression of key oncogenes involved in both the development and maintenance of cancer. Alli PM, et al., Oncogene, 24(1): 39-46 (2005).

[0132] Inhibitors of cancer metabolism, including inhibitors of LDH-A and inhibitors of fatty acid biosynthesis (or FAS inhibitors), are suitable for use in combination herein.

[0133] Cancer gene therapy involves the selective transfer of recombinant DNA / RNA using viral or non-viral gene delivery vectors to modify cancer cells for therapeutic purposes. Examples of cancer gene therapy include, but are not limited to, suicide gene therapy and oncolytic gene therapy, as well as adoptive T cell therapy.

[0134] As used herein, "immunomodulator" refers to any substance, including monoclonal antibodies, that affects the immune system. The CD96 binding proteins of the present invention may be considered immunomodulators. Immunomodulators may be used as anti-neoplastic agents for the treatment of cancer. For example, immunomodulators include, but are not limited to, antibodies or other antagonists against CTLA-4 (e.g., ipilimumab (YERVOY™)) and PD-1 (e.g., dostarlimab, nivolumab (OPDIVO™), pembrolizumab (KEYTRUDA™) and cemiplimab (LIBTAYO™). Other immunomodulators include, but are not limited to, antibodies or other antagonists against PD-L1, OX-40, LAG3, TIM-3, 41BB, and GITR.

[0135] As used herein, "PD-1 antagonist" refers to any chemical compound or biological molecule that blocks the binding of PD-L1 expressed on cancer cells to PD-1 expressed on immune cells (T cells, B cells, or NKT cells), and preferably also blocks the binding of PD-L2 expressed on cancer cells to immune cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include PDCD1, PD1, CD279, and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274, and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc, and CD273 for PD-L2. The human PD-1 amino acid sequence can be found at NCBI locus number: NP_005009. The human PD-L1 and PD-L2 amino acid sequences can be found at NCBI locus numbers: NP_054862 and NP_079515, respectively.

[0136] PD-1 antagonists useful in any of the aspects of the invention include monoclonal antibodies (mAbs) or antigen-binding fragments thereof that specifically bind to PD-1 or PD-L1, preferably specifically bind to human PD-1 or human PD-L1. The mAb may be a human antibody, a humanized antibody or a chimeric antibody and may comprise a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen-binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv and Fv fragments.

[0137] Examples of mAbs that bind human PD-1 and are useful in various aspects and embodiments of the invention are described in U.S. Patent No. 8,552,154; U.S. Patent No. 8,354,509; U.S. Patent No. 8,168,757; U.S. Patent No. 8,008,449; U.S. Patent No. 7,521,051; U.S. Patent No. 7,488,802; WO 2004072286; WO 2004056875; and WO 2004004771.

[0138] Other PD-1 antagonists useful in any of the aspects and embodiments of the invention include immunoadhesins that specifically bind to PD-1, preferably human PD-1, such as fusion proteins that contain the extracellular or PD-1-binding portion of PD-L1 or PD-L2 fused to a constant region, such as the Fc region, of an immunoglobulin molecule. Examples of immunoadhesin molecules that specifically bind to PD-1 are described in WO2010027827 and WO2011066342. Particular fusion proteins useful as PD-1 antagonists in the therapeutic methods, medicaments and uses of the invention include AMP-224 (also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.

[0139] Nivolumab is a humanized monoclonal anti-PD1 antibody marketed as OPDIVO™. Nivolumab is indicated for the treatment of some unresectable or metastatic melanomas. Nivolumab binds to PD-1, an Ig superfamily transmembrane protein, and blocks its activation by its ligands PD-L1 and PD-L2, resulting in T cell activation and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T cell activation and effector function through suppression of P13k / Akt pathway activation. Other names for nivolumab include BMS-936558, MDX-1106, and ONO-4538. The amino acid sequence and methods of use and production of nivolumab are disclosed in US Patent No. US8008449.

[0140] Pembrolizumab is a humanized monoclonal anti-PD1 antibody marketed as KEYTRUDA™. Pembrolizumab is indicated for the treatment of some unresectable or metastatic melanoma. The amino acid sequence and method of use of pembrolizumab are disclosed in U.S. Patent No. 8,168,757.

[0141] In one embodiment, the PD-1 antagonist comprises any one or combination of the following CDRs: CDRH1: SYDMS (sequence number 151). CDRH2: TISGGGSYTYYQDSVKG (sequence number 152). CDRH3: PYYAMDY (sequence number 153). CDRL1: KASQDVGTAVA (SEQ ID NO: 154) CDRL2: WASTLHT (SEQ ID NO: 155) CDRL3: QHYSSYPWT (SEQ ID NO: 156)

[0142] In one embodiment, the PD-1 antagonist comprises a heavy chain variable region CDR1 ("CDRH1") comprising an amino acid sequence having one or two amino acid mutation(s) ("CDR variants") relative to the amino acid sequence set forth in SEQ ID NO:151.

[0143] In one embodiment, the PD-1 antagonist comprises a heavy chain variable region CDR2 ("CDRH2") comprising an amino acid sequence having five or fewer, e.g., four or fewer, three or fewer, two or fewer, or one amino acid mutation(s) ("CDR variants") relative to the amino acid sequence set forth in SEQ ID NO: 152. In a further embodiment, CDRH2 comprises amino acids having one or two amino acid mutation(s) relative to the amino acid sequence set forth in SEQ ID NO: 152.

[0144] In one embodiment, the PD-1 antagonist comprises a heavy chain variable region CDR3 ("CDRH3") comprising an amino acid sequence having one or two amino acid mutation(s) relative to the amino acid sequence set forth in SEQ ID NO: 153 ("CDR variant").

[0145] In one embodiment, the PD-1 antagonist comprises a light chain variable region CDR1 ("CDRL1") comprising amino acids having one or two amino acid mutation(s) relative to the amino acids set forth in SEQ ID NO: 154 ("CDR variant").

[0146] In one embodiment, the PD-1 antagonist comprises a light chain variable region CDR2 ("CDRL2") comprising a sequence of amino acids having one or two amino acid mutation(s) relative to the amino acid sequence set forth in SEQ ID NO: 155 ("CDR variant").

[0147] In one embodiment, the PD-1 antagonist comprises a light chain variable region CDR3 ("CDRL3") ("CDR variant") comprising an amino acid sequence having three or fewer, e.g., one or two amino acid mutation(s), relative to the amino acid sequence set forth in SEQ ID NO: 156. In a particular embodiment, the CDRL3 comprises an amino acid sequence having one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 156. In a further embodiment, the variant CDRL3 comprises the amino acid sequence set forth in SEQ ID NO: 157.

[0148] In one embodiment, the PD-1 antagonist comprises a CDRH1 comprising an amino acid sequence having one amino acid mutation(s) relative to the amino acid sequence set forth in SEQ ID NO: 151; a CDRH2 comprising an amino acid sequence having up to five amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 152; a CDRH3 comprising an amino acid sequence having up to one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 153; a CDRL1 comprising an amino acid sequence having up to three amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 154; a CDRL2 comprising an amino acid sequence having up to one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 155; and / or a CDRL3 comprising an amino acid sequence having up to three amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 156.

[0149] In one embodiment of the invention, the PD-1 antagonist comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 158, CDRH1 (SEQ ID NO: 151), CDRH2 (SEQ ID NO: 151), and CDRH3 (SEQ ID NO: 153). In some embodiments, the anti-PD1 antibodies of the invention comprise a heavy chain variable region having at least 90% sequence identity to SEQ ID NO: 158. Suitably, the PD-1 antagonists of the invention may comprise a heavy chain variable region having about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:158.

[0150] PD-1 antagonist heavy chain (VH) variable region: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS (SEQ ID NO: 158)

[0151] In one embodiment, the PD-1 antagonist comprises a heavy chain variable region ("V") comprising an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:158. H In one embodiment, V H comprises an amino acid sequence having at least one amino acid mutation, for example, 1 to 5, for example, 1 to 3, particularly up to 2 amino acid mutations, relative to the amino acid sequence set forth in SEQ ID NO: 158.

[0152] In one embodiment of the invention, the PD-1 antagonist comprises CDRL1 (SEQ ID NO:154), CDRL2 (SEQ ID NO:155) and CDRL3 (SEQ ID NO:156) in a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 159. In one embodiment, the PD-1 antagonist of the invention comprises a heavy chain variable region of SEQ ID NO:158 and a light chain variable region of SEQ ID NO:159.

[0153] In some embodiments, the PD-1 antagonists of the invention comprise a light chain variable region having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 159. Suitably, the PD-1 antagonists of the invention may comprise a light chain variable region having about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:159.

[0154] PD-1 antagonist light chain (V L ) Variable region: DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK (SEQ ID NO: 159)

[0155] In one embodiment, the PD-1 antagonist comprises a light chain variable region ("V") comprising an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:159. L In one embodiment, V L includes an amino acid sequence having at least one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 159, such as 1 to 5, 1 to 3, etc., particularly up to 2 amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 159.

[0156] In one embodiment, the PD-1 antagonist comprises a VDG1 polypeptide having an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:158. H and V comprising an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:159. L In one embodiment, the PD-1 antagonist comprises a V H and / or V that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 159 L Includes.

[0157] In one embodiment, the PD-1 antagonist has the amino acid sequence set forth in SEQ ID NO:158. H and V having the amino acid sequence set forth in SEQ ID NO: 159 L Includes.

[0158] In one embodiment, the PD-1 antagonist is a monoclonal antibody comprising a heavy chain (HC) amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:160.

[0159] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 160)

[0160] In one embodiment, the HC comprises an amino acid sequence having at least one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 160, such as 1 to 10, such as 1 to 7, in particular up to 6 amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 160. In a further embodiment, the HC comprises an amino acid sequence having 1, 2, 3, 4, 5, 6 or 7 amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 160.

[0161] In one embodiment, the HC chain has a mutation at positions 380 and / or 385 of SEQ ID NO: 160. The asparagine residues at these positions may be modified, for example by deamidation (conversion of the asparagine (N) residue to an aspartic acid (D) residue). Thus, in one embodiment, the HC comprises the amino acid sequence of SEQ ID NO: 162 (N380D), SEQ ID NO: 163 (N385D) or SEQ ID NO: 164 (N380D and N385D).

[0162] In one embodiment, the PD-1 antagonist is a monoclonal antibody comprising a light chain (LC) amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:161.

[0163] DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 161)

[0164] In one embodiment, the LC comprises an amino acid sequence which has at least one amino acid mutation relative to the amino acid sequence set forth in SEQ ID NO: 161, such as 1 to 10, such as 1 to 5, in particular up to 3 amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 161. In a further embodiment, the LC comprises an amino acid sequence which has 1, 2 or 3 amino acid mutations relative to the amino acid sequence set forth in SEQ ID NO: 161.

[0165] In one embodiment, the PD-1 antagonist comprises a HC comprising an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 160, and a LC comprising an amino acid sequence having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 161. Thus, the antibody is an antibody having a heavy chain that is at least about 90% identical to the heavy chain amino acid sequence of SEQ ID NO: 160 and / or a light chain that is at least about 90% identical to the light chain amino acid sequence of SEQ ID NO:161.

[0166] In one embodiment, the PD-1 antagonist comprises a heavy chain amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:160 and / or a light chain amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:161.

[0167] In one embodiment, the PD-1 antagonist comprises the heavy chain sequence of SEQ ID NO: 160 and the light chain sequence of SEQ ID NO: 161. In one embodiment, the PD-1 antagonist is dostarlimab, which comprises the heavy chain sequence of SEQ ID NO: 160 and the light chain sequence of SEQ ID NO: 162.

[0168] Anti-PD-L1 antibodies and methods for making them are known in the art. Such antibodies to PD-L1 can be polyclonal or monoclonal, and / or recombinant, and / or humanized. PD-L1 antibodies are being developed as immunomodulatory agents for the treatment of cancer.

[0169] Exemplary PD-L1 antibodies are disclosed in U.S. Patent No. 9,212,224; U.S. Patent No. 8,779,108; U.S. Patent No. 8,552,154; U.S. Patent No. 8,383,796; U.S. Patent No. 8,217,149; U.S. Patent Application Publication No. 20110280877; WO Publication No. 2013079174; and WO Publication No. 2013019906. Further exemplary antibodies and methods of use against PD-L1 (also known as CD274 or B7-H1) are disclosed in U.S. Patent No. 8,168,179; U.S. Patent No. 7,943,743; U.S. Patent No. 7,595,048; WO Publication No. 2014055897; WO Publication No. 2013019906; and WO Publication No. 2010077634. Specific anti-human PD-L1 monoclonal antibodies useful as PD-1 antagonists in the methods of treatment, medicaments and uses of the invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C.

[0170] Atezolizumab is a fully humanized monoclonal anti-PD-L1 antibody commercially available as TECENTRIQ™. Atezolizumab is indicated for the treatment of some locally advanced or metastatic urothelial carcinomas. Atezolizumab blocks the interaction of PD-L1 with PD-1 and CD80. Other exemplary PD-L1 antibodies include avelumab (BAVENCIO™), durvalumab (IMFINZI™).

[0171] CD134, also known as OX40, is a member of the TNFR superfamily of receptors that, unlike CD28, is not constitutively expressed on resting naive T cells. OX40 is a secondary costimulatory molecule expressed 24-72 hours after activation, and its ligand, OX40L, is also not expressed on resting antigen-presenting cells but following their activation. Expression of OX40 is dependent on full activation of T cells; without CD28, OX40 expression is delayed and at quarter-fold levels. OX-40 antibodies, OX-40 fusion proteins and methods of using them are disclosed in U.S. Patent Nos. 7,504,101; 7,758,852; 7,858,765; 7,550,140; 7,960,515; WO 2012027328; and WO 2013028231.

[0172] Further examples of additional active ingredients (anti-neoplastic agents) for use in combination with or co-administration with the CD96 binding proteins of the present disclosure are antibodies or other antagonists to CD20, retinoids, or other kinase inhibitors. Examples of such antibodies or antagonists include, but are not limited to, rituximab (RITUXAN™ and MABTHERA™), ofatumumab (ARZERRA™), and bexarotene (TARGRETIN™).

[0173] Further examples of additional active ingredients (antineoplastic agents) for use in combination with or co-administered with the CD96 binding proteins of the present disclosure are Toll-like receptor 4 (TLR4) antagonists, including, but not limited to, aminoalkyl glucosaminide phosphates (AGPs).

[0174] AGP is known to be useful as a vaccine adjuvant and immunostimulant to stimulate cytokine production, activate macrophages, promote innate immune responses, and enhance antibody production in immunized animals. AGP is a synthetic ligand of TLR4. AGP and their immunomodulatory effects through TLR4 have been disclosed in patent publications such as WO2006016997, WO2001090129, and / or U.S. Pat. No. 6,113,918, and reported in the literature. Further AGP derivatives are disclosed in U.S. Pat. No. 7,129,219, U.S. Pat. No. 6,911,434, and U.S. Pat. No. 6,525,028. Some AGPs act as agonists of TLR4, while others are recognized as TLR4 antagonists.

[0175] A further non-limiting example of an additional active ingredient (anti-neoplastic agent) for use in combination or co-administration with a CD96 binding protein of the present disclosure is an antibody against ICOS.

[0176] The CDRs of murine antibodies against human ICOS with agonistic activity are shown in PCT / EP2012 / 055735 (WO 2012131004). Antibodies against ICOS are also disclosed in WO 2008137915, WO 2010056804, EP 1374902, EP 1374901 and EP 1125585.

[0177] Further examples of additional active ingredients (antineoplastic agents) for use in combination with or co-administration with the CD96 binding proteins of the present disclosure are poly ADP ribose polymerase (PARP) inhibitors. Non-limiting examples of such inhibitors include niraparib, olaparib, rucaparib, and talazoparib.

[0178] Further non-limiting examples of additional active ingredients (antineoplastic agents) for use in combination or co-administration with the CD96 binding proteins of the present disclosure are STING modulating compounds, CD39 inhibitors, and A2a and A2a adenosine antagonists.

[0179] Selected anti-neoplastic agents that may be used in combination with a CD96 binding protein or a pharma- ceutically acceptable salt thereof include, but are not limited to, abarelix, abemaciclib, abiraterone, afatinib, aflibercept, aldoxorubicin, alectinib, alemtuzumab, arsenic trioxide, asparaginase, axitinib, AZD-9291, belinostat, bendamustine, bevacizumab, blinatumomab, bosuti Nib, brentuximab vedotin, cabazitaxel, cabozantinib, capecitabine, ceritinib, clofarabine, cobimetinib, crizotinib, daratumumab, dasatinib, degarelix, denosumab, dinutuximab, docetaxel, elotuzumab, entinostat, enzalutamide, epirubicin, eribulin, filgrastim, flumatinib, fulvestrant, fluquinitinib, gemtuzumab ozogamicin, ibritumomab, ebull Rutinib, idelalisib, imatinib, irinotecan, ixabepilone, ixazomib, lenalidomide, lenvatinib, leucovorin, mechlorethamine, necitumumab, nelarabine, netupitant, nilotinib, obinutuzumab, olaparib, omacetaxine, osimertinib, oxaliplatin, paclitaxel, palbociclib, palonosetron, panitumumab, pegfilgrastim, peginterferon alfa-2b, pemetrexed , perixafor, pomalidomide, ponatinib, pralatrexate, quizartinib, radium-223, ramucirumab, regorafenib, rolapitant, rucaparib, sipuleucel-T, sonidegib, sunitinib, talimogene laherparepvec, tipiracil, topotecan, trabectedin, trifluridine, triptorelin, uridine, vandetanib, velaparib, vemurafenib, venetoclax, vincristine, vismodegib and zoledronic acid.

[0180] Treatment may be therapeutic, prophylactic or preventative. A subject is one in need thereof. Those in need of treatment may include individuals already suffering from a particular medical disorder as well as those who may develop the disorder in the future.

[0181] Thus, the disclosed methods, antigen binding proteins and compositions described herein may be used for prophylactic or preventative treatments, if identified. In this case, the disclosed methods, antigen binding proteins and compositions may be used to prevent or delay the onset of one or more aspects or symptoms of a disease. The subject may be asymptomatic. The subject may have a genetic predisposition to a disease. A prophylactically effective amount of the antigen binding protein is administered to such an individual. A prophylactically effective amount is an amount that prevents or delays the onset of one or more aspects or symptoms of a disease described herein.

[0182] The methods, antigen binding proteins, and compositions of the disclosure need not affect a complete cure or eradicate every symptom or manifestation of a disease to constitute a viable therapeutic treatment. As recognized in the art, a drug used as a therapeutic agent in a treatment method may reduce the severity of a given disease state, but need not eliminate every manifestation of the disease to be considered a useful therapeutic agent. Similarly, a treatment administered prophylactically need not be completely effective in preventing the onset of a disease to constitute a viable prophylactic agent. It is sufficient to merely reduce the impact of a disease in a subject (e.g., by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or to reduce the likelihood that a disease will occur or worsen (e.g., by delaying the onset of a disease).

[0183] Another aspect of the present disclosure is a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CD96 binding protein or pharmaceutical composition according to any one of the preceding aspects. A further aspect of the present disclosure is a method of treatment according to the preceding aspects, further comprising whether the subject expresses CD96.

[0184] Another aspect of the disclosure is a CD96 binding protein or a pharmaceutical composition according to any one of the preceding aspects for use in therapy or treatment of a disease.

[0185] Another aspect of the present disclosure is the use of a CD96 binding protein or a pharmaceutical composition according to any one of the preceding aspects in the manufacture of a medicament for use in the treatment of a disease.

[0186] Another embodiment of the present disclosure is a pharmaceutical composition comprising a therapeutically effective amount of a CD96 binding protein according to any one of the preceding embodiments.

[0187] One embodiment of the present disclosure is a method for treating a disease in a subject (such as a human subject), comprising administering to a subject in need thereof a therapeutically effective amount of a CD96 binding protein according to any one of the preceding aspects, or a pharmaceutical composition according to any one of the preceding aspects.

[0188] An embodiment of the present disclosure is a method for treating a disease in a subject, comprising administering to a subject (such as a human subject) in need thereof a therapeutically effective amount of a CD96 binding protein according to any one of the preceding embodiments or a pharmaceutical composition according to any one of the preceding embodiments. A further embodiment of the present disclosure is a method for treating a disease in a subject in need thereof, further comprising determining whether the subject expresses the CD96 binding protein. A further embodiment of the present disclosure is a CD96 binding protein or pharmaceutical composition according to any one of the preceding embodiments for use in therapy. A further embodiment of the present disclosure is a CD96 binding protein or pharmaceutical composition according to any one of the preceding embodiments for use in treatment of a disease. A further embodiment is the use of a CD96 binding protein or pharmaceutical composition according to any one of the preceding embodiments in the manufacture of a medicament for use in treatment of a disease. An additional embodiment of the present disclosure is a method or therapy for treating a disease, comprising administering to a subject a therapeutically effective amount of a CD96 binding or pharmaceutical composition according to any one of the preceding embodiments, wherein the disease to be treated is cancer. In a further embodiment, the cancer is a solid tumor (e.g., a recurrent, metastatic, or progressive solid tumor). The cancer may be liver cancer (e.g., HCC), ovarian cancer, lung cancer such as non-small cell lung cancer (NSCLC), kidney cancer (e.g., RCC), colon cancer, gastric cancer, bladder cancer, head and neck squamous cell carcinoma (HNSCC), or may be leukemia and / or any B-cell malignancy. EXAMPLES

[0189] Example 1 Generation of CD96-binding proteins Binding protein production Fully human antibodies specific for human CD96 were isolated from naive eukaryotic libraries using biotinylated recombinant human and cynomolgus CD96 in combination with cell sorting and FACS-based selection techniques. The heavy chain output from the naive eukaryotic library selection was shuffled against the light chain library and further selections were performed to identify optimal light chain pairings.

[0190] Affinity maturation was performed to improve the affinity / potency of the antibody. This involved incorporating CDRH3 (GAGYYGDKDPMDV in SEQ ID NO: 2) of antibody 42Y073-86F08-1 into a pre-generated library with diversity in CDRH1 or CDRH2. Further selections were performed on this diversified library, and lead molecules were identified and sequenced. The amino acid and nucleic acid sequences of the variable light and heavy chains of the lead molecules are shown in SEQ ID NOs: 1-96. The amino acid sequences of the CDR regions are shown in SEQ ID NOs: 97-150.

[0191] Fc selection During the selection of lead molecules, the binding proteins were evaluated as human IgG1 WT molecules or as Fc-disabled human IgG1 molecules. To generate the Fc-disabled molecules, amino acid residues at positions 234, 235, and 237, specifically L234 and L235, or L235 and G237, were mutated to alanine to generate hIgG1'LALA' (L234A / L235A) and hIgG1'LAGA' (L235A / G237A) Fc-disabled human IgG1 molecules. These binding proteins showed neutralization of CD96 binding and CD155 binding. Three CD96 binding proteins, 42Y073-86F08-66 (86F08-66), 42Y073-86F08-16 (86F08-16), and 42Y073-86F04-23 (86F04-23), were selected for further evaluation. The binding protein 42Y073-86F08-66 is also known as GSK 6097608 (monoclonal antibody). These three CD96 binding proteins were evaluated for primary T cell binding as well as CD155 neutralization activity using different IgG mutants (human IgG1, IgG2, IgG4PE, or IgG1 Fc nullified). As shown in Figure 1, mutations in the Fc did not affect binding to CD96-expressing cells or neutralization of CD155 binding to CD96-expressing cells.

[0192] Example 2 Characterization of CD96-binding proteins Binding to CHO cells expressing human or cynomolgus CD96 CHO cells expressing human CD96v2 or cynomolgus CD96v2 were prepared in PBS. Cynomolgus CD96v2 cells were stained with 1 μM violet proliferation dye (VPD450). Cells were diluted with pre-warmed medium (RPMI containing 10% fetal bovine serum) and further incubated for 10 min at 37° C., then centrifuged at 400 g for 5 min and resuspended in flow buffer (PBS+0.5% BSA+2 mM EDTA) to 1.5×106 / ml. Stained CHO-cyCD96 and unstained CHO-huCD96 cells were combined and added to wells of a 384-well assay plate with dilutions of test anti-CD96 binding proteins for 1 h at 4° C. Cells were further incubated with anti-IgG APC-conjugated antibody, and the amount of surface-bound antibody on each of the CHO-cyCD96 and CHO-huCD96 cells was determined by flow cytometry. Median fluorescence intensity (MFI) values ​​were fitted with a four-parameter logistic model to calculate the EC50 of binding. The data are summarized in Table 2.

[0193] Neutralization of human CD155 binding to CHO cells expressing human CD96v2 CD96 binding proteins were prepared in PBS in U-bottom 96-well plates. CHO cells expressing human CD96v2 were added and incubated for 30 min at room temperature. After washing the cells three times by centrifugation, human CD155-Fc-AF647 conjugate was added for another 30 min at room temperature. After three washes, cells were fixed and analyzed for levels of CD155-Fc-AF647 staining by flow cytometry. Median fluorescence intensity (MFI) values ​​were fitted using a four-parameter logistic model to calculate IC50 values. The data are summarized in Table 2.

[0194] Binding of CD96-binding proteins to primary human T cells Human PBMCs were isolated from leukocyte reduction filters using density gradient centrifugation with Histopaque-1077. +T cells were isolated using the Pan T cell Isolation Kit (Miltenyi) according to the manufacturer's instructions. Serial dilutions of test CD96-binding proteins were incubated with human T cells for 1 h at 4°C. After three washes in buffer, anti-human IgG-APC conjugates were added for 1 h at 4°C. After three washes, cells were fixed and analyzed for APC staining by flow cytometry. Median fluorescence intensity (MFI) values ​​were fitted using a four-parameter logistic model to calculate the EC50 of binding. The data are summarized in Table 2.

[0195] Table 2. Binding data and neutralization of human CD155 binding to hCD96v2-expressing CHO cells by CD96 binding proteins [Table 2]

[0196] Selection of 42Y073-86F08-66 for further characterization To aid in the selection of lead molecules, biophysical properties of anti-CD96 binding proteins were evaluated: immunogenicity, deamidation, glycosylation, oxidation, aspartic acid isomerization were predicted by in silico analysis, and aggregation, fragmentation and chemical degradation properties were evaluated in the following conditions: 50 mM sodium phosphate pH 7.5 and 50 mM sodium acetate pH 5.0 at either 10 mg / ml or 1 mg / ml, as well as in unstressed and stressed (heat stress at 40° C. for 2 weeks) conditions. Anti-CD96 binding proteins were expressed in a HEK transient system and purified using protein A affinity and size exclusion chromatography. Anti-CD96 binding proteins were scored as follows:

[0197] [Table 3]

[0198] [Table 4]

[0199] [Table 5]

[0200] Antigen Binding by BIAcore: A change in antigen binding within ±10% between non-stressed and stressed samples was considered to be within an acceptable range (low risk). Molecules outside this range may represent a potential risk due to loss of binding activity.

[0201] The data are summarized in Tables 6 and 7. In Table 6, the position of predicted risk in the sequence is identified (Kabat numbering). In Table 7, the following abbreviations are used for the observed risks and the conditions under which they were observed: Agg = aggregation; incr. %Mass = increased heterogeneity; Binding loss = binding loss observed beyond the assay limits; Binding incr. = increased binding (indicating a possible bias towards aggregation); HMwS = high molecular weight species; LmwS = low molecular weight species; Rh = hydrodynamic radius (larger radius indicates possible aggregation); PBS = phosphate buffered saline; U = unstressed; S = stressed; A = 50 mM sodium acetate (pH 5.0); and P = 50 mM sodium phosphate (pH 7.5).

[0202] 42Y073-86F08-66, 42Y073-86F08-16 and 42Y073-86F04-23 showed the lowest incidence tendency and the lowest in silico risk. However, 42Y073-86F08-66 was selected for progression and further characterization because the following attributes were observed: Acceptable levels of percentages of total high molecular weight species (HMwS; <5%), low molecular weight species (LmwS; <2.5%) and monomers (95%) as determined by analytical size exclusion chromatography (aSEC). · Expected size distribution (>98% in peak 2 by SEC) and hydrodynamic radius (4.5–7 nm) as determined by dynamic light scattering (DLS); Minimal unexpected changes in chemical heterogeneity between unstressed and stressed samples as determined by capillary isoelectric focusing (CIeF); and - For antigen binding, <10% change was determined by antigen binding assay.

[0203] [Table 6] JPEG2024167261000007.jpg179160

[0204] [Table 7] JPEG2024167261000009.jpg229160JPEG2024167261000010.jpg138160

[0205] Low epitope binning of CD96 binding proteins An epitope binning competition assay was performed to determine the epitope of CD96 that the anti-CD96 binding proteins presented herein bind. Briefly, HuCD96-His was incubated with the first CD96 binding protein at room temperature for 1 hour, and then the binding of the second binding protein captured on the Protein A sensor was measured by BLI. If binding of the second CD96 binding protein was observed, the two binding proteins were considered to be non-competitive and assigned to different epitope bins. If binding of the second CD96 binding protein was not observed, the two binding proteins were considered to be competitive and assigned to the same epitope bin. A self-binning control was included for each CD96 binding protein, using the same binding protein as both the first and second binding proteins.

[0206] Competition between all CD96 binding proteins was observed, with the exception of 42Y073-2B04-46, indicating that all but 42Y073-2B04-46 bind to similar epitopes on CD96. This data suggests that all CD96 binding proteins presented herein, with the exception of 42Y073-2B04-46, bind to the same epitope on CD96 or to a spatially proximate epitope, thereby inhibiting the binding of additional CD96 binding proteins (i.e., they belong to the same epitope bin). However, the finding that 42Y073-2B04-46 does not compete with the other CD96 binding proteins presented herein suggests that this clone binds to a distinct epitope on CD96 (and thus belongs to a distinct epitope bin). Thus, in conjunction with the data presented in Table 2, it will be understood that binding and neutralization of human CD155 binding to hCD96v2-expressing CHO cells by the CD96 binding proteins presented herein is not limited to binding to any particular epitope of CD96.

[0207] Further binding affinity studies of CD96-binding proteins to CD96 isoforms The binding affinity of 42Y073-86F08-66, a fully human IgG1 antibody with wild-type Fc expressed and purified from CHO cells, to recombinant CD96 was determined using a solution equilibrium titration (MSD-SET) assay. 42Y073-86F08-66 bound to recombinant human CD96v2 with an average KD of 20 pM and to recombinant cynomolgus monkey CD96v2 with an average KD of 278 pM (Figure 2). In addition, 42Y073-86F08-66 was demonstrated to bind to recombinant mouse CD96v2 with an average KD of 479 pM.

[0208] In surface plasmon resonance (SPR) assays, 42Y073-86F08-66 did not bind to the pathway homologues recombinant human CD155, human CD226, human TIGIT, or human nectin-1.

[0209] MSD-SET Assay Procedure: summary:MSD-SET (MSD Solution Equilibrium Titration) analysis was used to determine the affinity of these antibodies to human and mouse CD96 proteins at 25°C (as the dissociation rates were too slow to be measured by BIACORE at this temperature). MSD-SET determines the solution phase, equilibrium affinity of antibodies. The method relies on detection of free antigen at equilibrium in a titrated series of antibody concentrations.

[0210] procedure Biotinylated human CD96 protein was used at a constant concentration of 1.5 nM and cynomolgus monkey biotinylated CD96 protein was used at 3 nM. One in five antibody samples were titrated over a 22-point curve starting at 6 nM for human CD96 and cynomolgus monkey CD96. The titrated antibodies and CD96 protein were incubated at room temperature for 24 hours. After 24 hours, 5 nM antibodies were coated on standard binding MSD plates (Meso Scale Discovery, L15XA) for 30 minutes at room temperature. The plates were then blocked with STARTING BLOCK blocking buffer (Thermo Scientific, #37542) for 30 minutes with shaking at 700 rpm, followed by washing three times with wash buffer. The incubated solution was added to the MSD plate for 150 seconds with shaking at 700 rpm, followed by one wash. Antigen captured on the plate was detected by incubating the plate with SULFOTAG-labeled streptavidin (Meso Scale Discovery, R32AD-1) for 3 minutes. The plate was washed 3 times with wash buffer and then read on an MSD SECTOR IMAGER instrument using 1× Read Buffer T with detergent (Meso Scale Discovery, R92TC-1). Percent free antigen was plotted as a function of titrated antibody using GRAPHPAD PRISM software and fitted to a quadratic equation.

[0211] CD96-binding protein binds to HEK cells overexpressing the CD96 protein The binding of 42Y073-86F08-66 to known human or cynomolgus monkey cell membrane CD96 isoforms was determined by flow cytometry using HEK cells transfected with these different isoforms (Figure 3). Despite the maximum binding response to the expressed isoforms and the differences between experiments (most likely due to variations in expression efficiency), comparable binding activity was demonstrated for these CD96 isoforms, as indicated by the EC50 of 42Y073-86F08-66 (Table 8). Taken together, these data suggest that 42Y073-86F08-66 can recognize all membrane forms of CD96 presented in humans and cynomolgus monkeys.

[0212] [Table 8]

[0213] Binding affinity of CD96-binding proteins to native CD96 on human and cynomolgus monkey T cells To confirm that 42Y073-86F08-66 binds to native CD96 expressed on primary human and monkey cells, we used CD3 + T cells and subsets (CD4 + or CD8 + Binding of 42Y073-86F08-66 to human CD4 + and CD8 + 42Y073-86F08-66 bound with high affinity to T cells (EC50 of 47 pM and 45 pM, respectively) (Figure 4 and Table 9). 42Y073-86F08-66 has a higher potency (pM) for binding to primary human T cells compared to HEK cells overexpressing CD96 (nM) as a result of the relatively low expression of CD96 on primary cells compared to the expression of CD96 following transient introduction of CD96 isoforms under the control of a strong constitutive promoter element.

[0214] [Table 9]

[0215] To confirm that 42Y073-86F08-66 binds to CD96 in cynomolgus monkeys, binding to primary monkey T cells was determined. Based on the binding of 42Y073-86F08-66 to the commercially available anti-CD96 antibody 6F9, cynomolgus T cells were found to express much lower levels of CD96 compared to human T cells. Similar observations were made for rhesus T cells. To robustly quantify CD96-target engagement, purified cynomolgus CD3 + T cells were activated for 17 days using anti-CD2 / 3 / 28 beads to upregulate CD96 expression. 42Y073-86F08-66 binding was determined for three different activated T cell samples from cynomolgus monkeys, and 42Y073-86F08-66 binding was confirmed in all of these samples. Although there were differential maximum signals between samples, the EC50 was very similar (average 76.6 pM) and within 2-fold of that observed for human T cells (49.9 pM) (Figure 5).

[0216] Internalization of CD96-binding proteins upon binding to human T and NK cells The fate of 42Y073-86F08-66 after binding was determined in human PBMC cultures using imaging cytometry. Highly punctate staining with 42Y073-86F08-66 was observed in three cell populations (CD4 + T cells, CD8 + The staining pattern was observed on the cell membrane in all three defined cell populations (CD4 T cells and NK cells) and was maintained over a 45-hour time course (Figure 6). + , CD8 + Internalization of 42Y073-86F08-66-PE was slow and incomplete over the 45 hour time course in all 42Y073-86F08-66 cells (T cells and NK cells). These data suggest that 42Y073-86F08-66 internalization is slow compared to other antibodies targeting T cell surface receptors.

[0217] CD96-binding protein inhibits the binding of the CD96 ligand CD155 to CD96-expressing cells In primary human T cells, precomplexation of 42Y073-86F08-66 to membrane CD96 was demonstrated to inhibit the latter from binding to its ligand, recombinant human CD155:Fc (IC50 0.16 nM) (Figure 7).

[0218] Disruption of established CD96:CD155 interactions by CD96-binding proteins When CD155:Fc was pre-bound to primary human T cells, 42Y073-86F08-66 was able to compete with CD155 in a dose-dependent manner (IC50 1.93 nM) (Figure 8), indicating that 42Y073-86F08-66 can displace CD96-bound CD155, the natural ligand of CD96.

[0219] Fc receptor binding by CD96 binding protein 42Y073-86F08-66 is a fully human IgG1 antibody with WTFc and is therefore predicted to bind to relevant Fc receptors.

[0220] Using a panel of recombinant cell lines (Promega) expressing activating human Fcγ receptor reporters (FcγRI, FcγRIIa(R), FcγRIIa(H), FcγRIIIa(V) and FcγRIIIa(F)), we demonstrated that binding of 42Y073-86F08-66 to CD96 on primary human T cells did not result in activation of human Fcγ receptors (Figure 9). In contrast, a control anti-CD52 antibody (Campath) efficiently induced FcγR activation signals in all of the Fcγ receptor-expressing cells tested.

[0221] It was important to confirm the findings of the reporter assay by cell killing assays using primary human cells. In fresh human PBMC cultures containing NK cells, there was no evidence of increased cell death of either CD4 or CD8 T cells in the presence of 42Y073-86F08-66 (Figure 10). In the same experiment, both CD4 and CD8 T cells were effectively depleted in the presence of an anti-CD52 antibody (Campath).

[0222] The first step of the classical pathway of complement activation is mediated by the binding of complement component C1q to antibody-opsonized cells. The affinity of human complement component C1q binding to 42Y073-86F08-66 was determined using SPR and was higher (KD 94.4 nM) than the IgG1 WT isotype control (KD 643.5 nM). Using primary human T cells as targets, we investigated the potential of 42Y073-86F08-66 to induce complement-dependent cytotoxicity (CDC).

[0223] In a CDC assay using human serum as a source of complement, there was no evidence of depletion of either CD4 or CD8 T cells by 42Y073-86F08-66, whereas a control anti-CD52 antibody efficiently mediated depletion of both subsets (Figure 11). Collectively, these data suggest that there is little risk of ADCC- or CDC-mediated depletion of 42Y073-86F08-66-modified CD96-expressing T cells.

[0224] Example 3 In vitro efficacy and mechanistic studies of CD96 binding proteins In vitro efficacy of 42Y073-86F08-66 in primary mixed human PBMC-MLR assays The effect of 42Y073-86F08-66 expressed and purified from CHO and HEK cells was tested in a primary PBMC assay without the addition of CD155, anti-CD3 or anti-TIGIT. In this assay, PBMCs from eight different human donors were mixed together and added to the wells with the different antibodies in solution. After 3 days of incubation, IFNγ was measured in the supernatants using homogenous time-resolved fluorescence (HTRF) detection. In this assay, anti-CD3 was not required because PBMCs were activated by MHC mismatch between the different donors. The potency was similar for both CD96 binding proteins (expressed in CHO or HEK cells) (Figure 12). Both appeared to be more potent than Tecentriq (EC50 49 pM). In separate repeats of the same experiment, the EC50 was 22 pM, 10 pM, and 140 pM for 42Y073-86F08-66 (HEK), 42Y073-86F08-66 (CHO), and Tecentriq, respectively (Figure 12). Cell viability was also measured after 3 days, and only Tecentriq showed some reduction in cell viability. Neither the anti-CD96 mAb nor the isotype control reduced cell viability, consistent with the lack of cell depletion observed in the ADCC assay.

[0225] CD4 + T cells are the major source of 42Y073-86F08-66-induced IFNγ in a mixed human PBMC-MLR assay To address the question of which cell subpopulations were responsible for the observed increase in IFNγ secreted into the supernatant upon 42Y073-86F08-66 (HEK) and 42Y073-86F08-66 (CHO) treatment in PBMC assays, cell depletion studies were performed. PBMCs from four different donors were separately depleted of CD4 + T cells or CD8 + T cells were depleted. Depletion was performed using human CD4 or CD8 MicroBeads (Miltenyi), and CD4 + or CD8 +The purity of T cell depletion was verified by flow cytometry. + Deplete cells by 98.5-99.5% and isolate CD8 from PBMCs + The data from the mixed PBMC-MLR assays with T cell depletion showed that CD4 + T cells were the predominant subset responsible for IFNγ induction by 42Y073-86F08-66 (HEK) in this assay, whereas CD8 + T cells showed this was not the case (Figure 13).

[0226] Flow cytometry studies to understand the mechanism of action of CD96 binding proteins To further understand the mechanism of action for anti-CD96, flow cytometry studies were performed to study the expression changes of cell surface receptors as well as intracellular cytokines in different cell populations in human PBMCs. The same mixed PBMC-MLR assay system was used. For cell activation by MHC mismatch, PBMCs from eight donors were mixed together. After addition of anti-CD96 or isotype control antibodies, PBMCs were incubated for 0 days (baseline) or 3 days, followed by fixing cells and quantification of various markers by flow cytometry. To confirm the activity of 42Y073-86F08-66 in this experiment, secreted IFNγ and granzyme B in the supernatant were also measured by MSD and ELISA after 3 days. As previously observed, 42Y073-86F08-66 enhanced IFNγ and granzyme B release (Figure 14). No increase in secreted IFNγ or granzyme B was observed with anti-TIGIT mAb clone 1F4 (Roche, hIgG1-WT).

[0227] To understand which cell populations contributed to the increase in IFNγ by 42Y073-86F08-66, we measured intracellular staining of IFNγ in different cell populations by flow cytometry. Even in the IgG1 isotype control-treated group, there was a significant increase in IFNγ on day 3 compared to day 0. + CD4+ , CD8 + There was a significant increase in the expression (data not shown) and frequency of CD4+ and NK cell subsets, indicating lymphocyte activation by mixing PBMCs from different donors (Figure 15). Treatment with 42Y073-86F08-66 suppressed all three immune subsets, namely CD4+, CD4+, and NK cell subsets. + , CD8 + and IFNγ in NK cells + Anti-TIGIT antibody (clone 1F4) further significantly increased the frequency of IFNγ in the NK cell population (Figure 15). + It only increased the frequency of the cells.

[0228] Furthermore, CD96 expression was significantly increased in all three cell populations upon cell activation on day 3 compared to day 0, a profile typically observed for checkpoint proteins. Anti-CD96 antibody treatment significantly increased expression in all three subsets, CD4+, CD5+, and CD6+ cells compared to the corresponding isotype control groups. + , CD8 + and CD96 MFI and CD96 in NK cells + 42Y073-86F08-66 treatment significantly reduced the cell frequency. Fc-invalidating 86F08-66-LAGA antibody treatment also led to a reduction in the CD96 profile, but the reduction in CD96 expression in the 42Y073-86F08-66 treated group was much more significant (Figures 16-17). Anti-TIGITab clone 1F4 showed no effect. This apparent reduction in CD96 expression by 42Y073-86F08-66 treatment could be due to competition between the anti-CD96 detection antibody and the therapeutic Ab indicating receptor occupancy by the therapeutic antibody, or due to internalization of the CD96 receptor by binding of 42Y073-86F08-66. The detection antibody used in the analysis was the commercially available Ab clone 6F9 (BD Biosciences).

[0229] CD226 is one of the major activating receptors in NK cells, but its role in T cells has not been well established. To understand the mechanism in more detail, we investigated the CD226 activation of NK cells in a PBMC-MLR assay. +We focused on characterizing the CD226 population. + CD96 + Treatment with 42Y073-86F08-66 increased the frequency of NK cells by upregulating CD226 at day 3 compared to both the isotype control (5.91% / 46.4%=0.127) and the 86F08-66 IgG1 LAGA Fc-neutralizing antibody (13.8% / 47.2%=0.29). + Single positive NK cells vs. CD226 + CD96 + This resulted in a higher ratio of double positive NK cells (26.2% / 25.2%=1) (Figure 18). Since CD226 is an activating receptor in the axis and CD96 is a putative checkpoint receptor in the same axis, CD226 + Single positive cells were 226 + CD96 + The double positive cells may represent more activated NK cells.

[0230] 42Y073-86F08-66 treatment was performed on day 3 after 42Y073-86F08-66 treatment with CD226 + IFNγ in NK cells + Cells and GrzB + This resulted in a higher frequency of cells. No effect was observed with the Fc-disabled IgG1-LAGA lead antibody (86F08-66-LAGA).

[0231] Overall, 42Y073-86F08-66 treatment resulted in more IFNγ+GrzB+ double positive cells among total NK cells on day 3 compared to isotype control Ab or Fc-disabled IgG1-LAGA lead antibody (86F08-66-LAGA) (Figure 19).

[0232] CD155-PBMC assay for screening of CD96-binding proteins To determine the inhibitory effect of plate-bound CD155-Fc on IFNγ production in human PBMCs, round-bottom 96-well non-TC plates (#351177) were coated with different doses of rhCD155-Fc (cat. no. 9174-CD-050, R&D Systems) overnight at 4°C and blocked with AIM-V medium (cat. no. 12055-091, Thermo Fisher) containing 5% BSA (cat. no. 9576, Sigma) for 30 min at room temperature. PBMCs (cat. no. 70025, Stemcell Technologies) were pretreated with CD96 binding protein, anti-TIGIT mAb (cat. no. MAB7898, R&D Systems) or isotype control for 10 min at room temperature and plated at 2 × 10 in AIM-V medium containing 0.01 μg / ml of anti-CD3 MAb. 5 Cells / well were added to wells and cultured for 3 days. Supernatants were collected and stored at -20°C for measurement of IFNγ and granzyme B by MSD or ELISA. The inhibitory effect of plate-bound CD155-Fc on IFNγ production in human PMBCs is shown in Figure 20. CD96 binding protein appears to alleviate CD155-Fc-mediated IFNγ inhibition (vs. IgG1-WT isotype control antibody) (Figure 26). Further assays were performed to determine the ability of CD96 binding protein to alleviate CD155-Fc-mediated TNFα suppression (in the presence of anti-TIGIT mAb) (Figure 27). Further assays performed with (and without) anti-TIGIT mAb show that the ability of CD96 binding protein to alleviate CD155-Fc inhibition on IFNγ production is evident both in the presence and absence of anti-TIGIT mAb (Figure 28).

[0233] Activity of CD96-binding proteins in human tumor-infiltrating lymphocyte (TIL) assays The tumor microenvironment (TME) is immunosuppressive, and tumor-infiltrating lymphocytes (TILs) found in tumors are often immune-dysfunctional or "exhausted." A primary human TIL assay was developed to evaluate the potential therapeutic effect of 42Y073-86F08-66 in vitro. Fresh primary resected tumors were mechanically and enzymatically dissociated into a single cell suspension containing both tumor cells and TILs. TILs in the cell suspension were gently activated with a suboptimal dose of soluble anti-CD3 (clone HIT3a) and seeded in triplicate in 96-well ultra-low attachment round-bottom spheroid-forming plates. Antibodies were then added to the wells, and IFNγ was measured in the supernatants 6 days later. 42Y073-86F08-66 was evaluated in this assay at three concentrations (10, 2, and 0.5 μg / mL) either alone or in combination with either anti-PD-1 (Keytruda / pembrolizumab) (10 μg / mL) or anti-TIGIT (100 μg / mL). Anti-PD-1 alone was also tested as a positive control for induction of IFNγ over anti-CD3 alone. Appropriate isotype controls were also included.

[0234] A total of six tumors (four endometrial and two renal) were tested in this assay. For four endometrial tumors, anti-PD-1 together with anti-CD3 treatment induced IFNγ levels comparable to anti-CD3 alone, indicating that anti-CD3 stimulation may be too high and further technical development may be required. In one of two renal tumors (sample 5001063), anti-PD-1 treatment increased IFNγ levels higher than anti-CD3 treatment alone (p<0.05 by one-way Anova). Furthermore, anti-PD-1 + 42Y073-86F08-66 (10 μg / mL) combination treatment significantly (p<0.001 by one-way Anova) enhanced IFNγ production to 7764 pg / mL, higher than 10 μg / mL of 42Y073-86F08-66 alone (599 pg / mL), anti-PD-1 alone (2692 pg / mL), or the simple additive effect of the two (Figure 21). For the second renal tumor (sample 1002273), anti-PD-1 treatment did not enhance IFNγ production over anti-CD3 stimulation alone. These tumors were not prescreened for PD-1 axis expression or CD96 axis expression. The complexity of these TIL assays is widely recognized, and variability in response to anti-PD-1 treatment among patient tumors has been observed. This is not surprising, given that the response rate to anti-PD-1 (Keytruda) in unscreened patients is less than 25%.

[0235] Example 4 In vivo efficacy and mechanism studies Bioluminescence imaging study of CD96-binding proteins in a NK cell-dependent B16F10 melanoma lung colonization model NK cells are part of the innate lymphoid cell family and play a prominent role in controlling early tumor growth and metastatic spread through cytotoxic activity and release of inflammatory cytokines. A frequently used in vivo model to study NK cell-dependent anticancer activity is the B16F10 melanoma lung colonization model. This model is also described in the CD96 cancer related publication (Blake SJ, et al. 2016). We decided to use the same model to study 42Y073-86F08-66 (produced in HEK cells) activity in vivo. To measure the efficacy of anti-CD96 mAbs in controlling lung metastases in real time and in a more quantitative way, instead of using regular B16F10 melanoma cells, we used B16F10 cells encoding red firefly luciferase (RFluc) to allow in vivo imaging of luciferase signals from the lungs, which indicate tumor burden.

[0236] Up to 500,000 B16F10 RFluc metastatic melanoma cells were administered via tail vein, followed by in vivo bioluminescence imaging on days 0 (within a maximum of 15 minutes after cell injection), 7, 10, 14, 17, and 20. (Initial cell colony formation occurs in the lungs as early as 15 minutes after injection, from previous model development studies). The administration frequency was twice weekly (Figure 22). After in vivo imaging on day 20, mice were harvested for ex vivo bioluminescence imaging of mouse lungs.

[0237] In this system, a specific immune cell type (CD4 + , CD8 + To further evaluate the role of CD4+, CD5+, and NK cells, we used established antibody treatment methods to detect CD4+, CD5+, and NK cells. + cells, CD8 + cells, NK cells or CD4 + and CD8 + Subsequent flow cytometric analysis revealed that CD4 + / CD8 + Depletion of NK cells and T cells in the depleted group was confirmed.

[0238] Bioluminescence imaging on day 14 revealed a significant increase in the signal in the lungs of the NK cell depleted group (Figure 23). The presence of lower lung signal (p / s) was associated with fewer metastases. Indeed, 19 out of 20 mice did not survive to the end of the study, likely due to severe lung tumor burden. This data clearly supports the important role of NK cells as the primary participants in the suppression of lung metastases in this model.

[0239] In vivo bioluminescence imaging performed on day 14, when NK-depleted mice were still alive, showed that for the NK-depleted group, 42Y073-86F08-66 (produced in HEK cells) treatment significantly reduced lung metastases compared to isotype control treatment (*P<0.05) (Figure 24, A). A trend was also observed for the non-depleted group, but it was not statistically significant. At day 20, for the non-depleted group, the lung signal was reduced in the 42Y073-86F08-66 treated group, but it was not statistically significant (ns). For the T cell-depleted group, 42Y073-86F08-66 significantly reduced the lung signal compared to the isotype control ( ** P<0.01) (FIG. 24, B). The presence of lower lung signals (p / s) was associated with fewer metastases. Digital photography of the lungs after sacrificing the mice on day 20 confirmed the efficacy of 42Y073-86F08-66 (FIG. 25).

[0240] Example 5 Summary of efficacy data and mechanisms Evidence for activity of 42Y073-86F08-66 on T cells Human: CD96 is expressed at readily detectable levels on both CD4 and CD8 T cells in PBMCs as well as in the tumor microenvironment. In TILs, in addition to NK cells, CD96 was found on CD8, CD4 Teff cells as well as Tregs. Consistent with the expression pattern, flow cytometry analysis showed that 42Y073-86F08-66 treatment significantly increased IFNγ expression in mixed PBMC-MLR assays. +CD4 + and CD8 + It was shown to increase the percentage of T cells that express CD4+ T cells. Depletion studies showed a dramatic loss of IFNγ release by 42Y073-86F08-66 in a mixed PBMC-MLR assay when CD4+ T cells were depleted. However, CD8 depletion had little effect in this particular assay. Mice: In an in vivo setting, for the B16F10 lung colorization assay, 14 days after tumor cell injection, when NK-depleted mice were still alive, 42Y073-86F08-66 treatment still showed a statistically significant reduction in lung metastases compared to isotype control when NK cells were depleted, likely by activating T cells.

[0241] Evidence for NK cell activity Human: CD96 is expressed at readily detectable levels on NK cells in PBMCs and in the tumor microenvironment. Indeed, among TIL subpopulations, the highest levels of CD96 expression were found on NK cells. CD226 is one of the major activating receptors for NK cells, and strong NK activity target validation data for CD96 have also been reported in the literature. In an in vitro setting, intracellular cytokine staining studies using flow cytometry showed an increase in IFNγ+GrzB+NK cells upon 42Y073-86F08-66 treatment in a mixed PBMC-MLR assay. Mice: In an in vivo setting, using the B16F10 lung colonization model, a well-recognized and highly NK cell-dependent model, we showed that 42Y073-86F08-66 was able to significantly suppress lung metastasis when both CD4 and CD8 T cells were depleted, strongly suggesting that this was mediated through NK activity.

[0242] Example 6: Anti-CD96 mAb - Non-clinical Toxicity Studies GSK6097608B (hereafter referred to as GSK6097608, equivalent to 42Y073-86F08-66) is a monoclonal antibody (mAb) targeting cluster of differentiation (CD) 96 that is being developed for the treatment of cancer. Intravenous (IV) dose-ranging and 4-week repeat dose toxicity studies with anti-CD96 mAb were performed in cynomolgus monkeys and BALB / c mice. Additionally, single dose PK and PD studies were performed in monkeys. In vitro CRA in human blood samples and combination CRA with dostarlimab (anti-PD-1 mAb) were performed. Evaluation of the binding profile was performed using follow-up confirmatory binding assays using human microarrays. Preliminary immunohistochemistry (IHC) studies were performed using selected human and cynomolgus monkey tissues.

[0243] BALB / c mice and cynomolgus monkeys were selected as preclinical species to evaluate the safety profile of anti-CD96 mAbs. Because anti-CD96 mAbs cross-react with similar affinity to human and monkey CD96 receptors, monkeys were considered to be suitable preclinical species to evaluate the potential toxicity of anti-CD96 mAbs. Based on the initial PK and efficacy study results, as well as the in vitro binding of anti-CD96 mAbs to mouse splenocytes and cytokine production by mouse splenocytes pre-stimulated with CD3 / CD28 and incubated with anti-CD96 mAbs, further preclinical safety studies were performed in BALB / c mice.

[0244] The anti-CD96 mAb was well tolerated in monkey toxicity studies after four weekly doses up to 100 mg / kg / week. + T cells, CD4 +CD96 receptor occupancy (RO) or target binding on T and NK cells was maintained throughout all studies. A low incidence of low titer anti-drug antibodies (ADA) was observed that did not affect receptor binding or systemic exposure. There was no change in the number of circulating cells expressing CD96, and no histopathology findings in tissues including primary and secondary immune tissues, suggesting a low risk of crystallizable fragment (Fc)-dependent depletion of CD96-expressing effector cells. Anti-CD96 mAb was tolerated in mice at 100 mg / kg / week for 4 weeks; however, a lower dose of 10 mg / kg / week caused immune-mediated anaphylaxis due to ADA or circulating immune complexes after the third weekly dose.

[0245] An in vitro CRA was performed using PBMCs isolated from five male and five female healthy donors to evaluate anti-CD96 mAb alone, dostarlimab alone, and the combination of anti-CD96 mAb and dostarlimab. Compared to media controls, there was a minimal increase in the immunomodulatory anti-inflammatory cytokine interleukin (IL)-10 in most donors receiving each antibody treatment, and a mild to moderate treatment-related increase in IL-6 and / or tumor necrosis factor alpha (TNF-α) for one donor in the anti-CD96 mAb alone and dostarlimab alone conditions, respectively. These levels were lower than the anti-CD3 and anti-CD28 positive controls, which induced a pan-cytokine response. Overall, there was no enhancement of cytokine responses with combination treatment; however, the one donor with increased IL-6 and TNF-α in the anti-CD96 mAb alone condition was also more sensitive to combination treatment. Results indicate an overall low risk of cytokine release syndrome (CRS), although there may be individual participant responses to cytokine induction.

[0246] Based on tolerability and the absence of relevant adverse findings, the no observed adverse effect level (NOAEL) was determined to be 100 mg / kg / week (highest dose tested) in both monkeys (sex mean 4-week mean area under the curve [AUC] 0-168 h: 580 mg h / mL [range: 483-647 mg h / mL] and Cmax: 5.54 mg / mL [range: 5.10-6.54 mg / mL]) and mice (sex mean 4-week mean AUC 0-168 h: 319 mg h / mL and Cmax: 2.98 mg / mL).

[0247] Example 7: First time in human study of anti-CD96 mAb as monotherapy and in combination with dostarlimab (also known as TSR042) GSK6097608B (hereafter referred to as GSK6097608, equivalent to 42Y073-86F08-66) is a monoclonal antibody (mAb) targeting cluster of differentiation (CD) 96 (anti-CD96 mAb) in development for the treatment of cancer. Binding of CD96 by its related receptor, CD155, functions as an "off switch" or immune checkpoint, downregulating immune responses. This CD96 antagonist antibody was developed to block the CD96:CD155 inhibitory axis and increase the antitumor activity of T cells and natural killer (NK) cells. This first-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK6097608 given as monotherapy and in combination with dostarlimab. Dostarlimab (also known as TSR-042) is an investigational humanized mAb of the immunoglobulin (Ig) G4 (IgG4) isotype that has high affinity for binding to programmed cell death protein 1 (PD-1), resulting in inhibition of binding to programmed cell death ligand (PD-L) 1 and PD-L2. Based on the observed anticancer activity of other antibodies in the same class, dostarlimab is expected to show clinical activity in a broad range of cancers.

[0248] Based on evidence supporting the molecular interplay between pathways and the utility of addressing diverse immune populations, GSK6097608 may not only work in concert with PD-(L)1 (programmed cell death protein 1 and / or programmed cell death ligand 1) blockade, but may also benefit patients who are refractory or have developed resistance to current T cell-based therapies.

[0249] Scientific rationale for combination with anti-PD1 Despite the therapeutic benefits of blocking immune checkpoint pathways PD-(L)1 and CTLA-4 across multiple tumor types, most patients do not respond to monotherapy with checkpoint inhibitors, and strategies to increase their activity through combination approaches are being actively explored. The rationale for combining an anti-CD96 mAb (GSK6097608) with a drug designed to block the PD-(L)1 pathway (dostarlimab, an anti-PD-1 mAb) is based on evidence supporting molecular interactions between the pathways, the utility of addressing diverse immune populations, and therapeutic complementarity between intervention strategies.

[0250] At the mechanistic level, PD-1 signaling has been shown to dephosphorylate the intracellular domain of CD226, attenuating its costimulatory potential following CD96-mediated CD155 redirection. Notably, CD96 expression is upregulated in melanoma tumor tissues following nivolumab (anti-PD-1) treatment, implicating the CD96 inhibitory axis as a possible adaptive resistance mechanism to PD1 blockade. Reciprocal upregulation of pathway components may also be observed upon CD96 blockade, as GSK6097608-mediated induction of interferon gamma (IFNγ) may upregulate PD-L1 expression. Taken together, these observations suggest that simultaneous blockade of CD96 and PD-(L)1 may be necessary to enable an effective antitumor immune response.

[0251] Clinical Experience with Dostarlimab Dostarlimab is currently being developed as a monotherapy for patients with recurrent or progressive solid tumors, including endometrial cancer (microsatellite stable and microsatellite instability-high [MSI-H] tumors), non-small cell lung cancer (NSCLC), and non-endometrial MSI-H solid tumors and polymerase ε-mutated cancers. In addition, dostarlimab is being developed as combination therapy with other therapeutic agents for patients with advanced solid tumors (including melanoma, NSCLC, and colorectal cancer) or advanced or metastatic cancers (including endothelial ovarian cancer, triple-negative breast cancer, and urothelial carcinoma).

[0252] As of January 21, 2019, there were four ongoing phase 1 trials, two ongoing phase 2 trials, and one ongoing phase 3 trial with dostarlimab.

[0253] The safety and tolerability of dostarlimab have been evaluated in over 627 participants with advanced cancer who received at least one dose of dostarlimab. Of the 335 participants treated with dostarlimab monotherapy in FTIH Study 4010-01-001 (GARNET), 93.7% reported at least one treatment-emergent adverse event (TEAE), with fatigue, nausea, and diarrhea being the most frequently reported events. Study intervention-related TEAEs ≥ grade 3 were reported in 36 participants (10.7%). The majority of study intervention-related TEAEs ≥ grade 3 occurred in only two participants each, with the exception of fatigue (six participants), increased alanine aminotransferase (ALT) (four participants), anemia (four participants), increased aspartate aminotransferase (AST) (three participants), and increased lipase (three participants). Serious adverse events (SAEs) occurred in 106 participants (31.6%); in 21 of these participants, these SAEs were considered study intervention related. All study intervention related SAEs occurred in one participant each, except for pneumonia (4 participants), dyspnea (2 participants), fever (2 participants), and rash maculopapular (2 participants). Twenty-three participants (6.9%) treated with dostarlimab monotherapy experienced at least one immune-related adverse event (irAE) with a severity of ≥ grade 3; for 18 of the 23 participants with ≥ grade 3 irAEs, the adverse event (AE) was assessed as study intervention related by the investigator. The majority of ≥ grade 3 irAEs were reported in ≤ 2 participants each. irAEs ≥ grade 3 reported in > 2 participants included increased AST (4 participants), increased ALT (4 participants), increased lipase (4 participants), and rash (3 participants).

[0254] Of 292 participants treated with dostarlimab in combination with other therapeutic agents, 94.5% reported at least one TEAE, with fatigue, nausea, and dyspnea events being the most frequently reported. SAEs occurred in 108 participants (37.0%); in 20 of these 108 participants, the SAE was related to the study intervention.

[0255] Based on safety data from human experience and available nonclinical pharmacology and toxicology information, dostarlimab demonstrated an acceptable clinical and nonclinical safety profile that is believed to be consistent with the safety experience of the approved mAb PD-1 inhibitors, pembrolizumab and nivolumab.

[0256] Based on the observed antitumor activity of other antibodies in the same class, dostarlimab is expected to show clinical activity in a broad range of cancers. Preliminary efficacy data from 15 participants with MSI-H endometrial cancer and 24 participants with NSCLC who had at least one tumor evaluation were presented at the American Cancer Society's April 2018 annual meeting. Responses were assessed by investigators using the Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST). Among the 15 participants with MSI-H endometrial cancer, the overall response rate was 47%, consisting of all partial responses (PR); 20% had stable disease (SD), and 33% had disease progression. Among the 24 participants with NSCLC, the ORR was 29%, consisting of all partial responses (PR); 42% had SD, and 17% had disease progression. Thus, preliminary efficacy data from participants with NSCLC treated with dostarlimab appear to be comparable to the reported efficacy of other PD(L)1 inhibitors, such as pembrolizumab, in participants with advanced and recurrent cancer (ORR: 19%) [Herbst, 2016].

[0257] Objectives and Endpoints This FTIH open-label dose-escalation study will evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of GSK6097608 as monotherapy (ArmA) or in combination with dostarlimab (ArmB) in participants with locally advanced, recurrent, or metastatic solid tumors; the study will be used to define the recommended phase 2 dose (RP2D).

[0258] [Table 10] JPEG2024167261000014.jpg220160Abbreviations:ADA = anti-drug antibodies;AE = adverse events;AUC = area under the curve;Cmax = maximum concentration;Cmin = minimum concentration;DCR = disease control rate;DLT = dose-limiting toxicity;DNA = deoxyribonucleic acid;DoR = duration of response;IHC = immunohistochemistry;iRECIST = modified Response Evaluation Criteria in Solid Tumors, version 1.1 for immune-based therapeutics;IV = intravenous (ly);ORR = overall response rate;PD = efficacy;PK = pharmacokinetics;RNA = ribonucleic acid;RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1 1.1);RP2D=recommended phase 2 dose;SAE=serious adverse event;t1 / 2=half-life;TTP=time to progression;TTR=time to response.

[0259] Overall Design This is an FTIH, open-label, non-randomized, multicenter study designed to investigate the safety, tolerability, PK, PD, and preliminary clinical activity of escalating doses of GSK6097608 administered IV as monotherapy (Arm A) or in combination with dostarlimab (Arm B) in participants with locally advanced, recurrent, or metastatic solid tumors.

[0260] GSK6097608 administered IV every 3 weeks (Q3W) will be evaluated as monotherapy in escalating doses (Arm A) under the guidance of a Dose Escalation Committee (DEC). To further evaluate PK and PD, additional participants will be enrolled in the PK / PD cohort at RP2D (maximum of 15 participants) in the following tumor types: non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), or other tumor types defined based on emerging non-clinical and / or clinical data. Additional participants may also be enrolled in the PK / PD cohort at previously cleared dose levels for dose exploration (maximum of 15 participants per cohort). These additional participants will contribute to the evaluation of safety and preliminary anti-cancer activity, as well as the overall PK / PD data profile.

[0261] Once a dose of GSK6097608 that is tolerable and has adequate drug exposure based on PK data is identified, enrollment into the combination arm (Arm B) may begin. In Arm B, escalating doses of GSK6097608 will be evaluated with a fixed dosing regimen of dostarlimab. To further evaluate PK and PD, additional participants will be enrolled in the PK / PD cohort at RP2D (maximum of 15 participants) in the following tumor types: NSCLC, HNSCC, or other tumor types defined based on new nonclinical and / or clinical data. In addition to the cohort treated at RP2D, participants may also be enrolled in the PK / PD cohort at previously cleared dose levels (maximum of 15 participants per cohort) for dose exploration.

[0262] These additional participants will contribute to the evaluation of safety and preliminary anti-cancer activity, as well as the overall PK / PD data profile.

[0263] Assessment of disease status at screening and during study intervention visits will be performed by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 and modified RECIST for Immunotherapy (iRECIST). The decision to discontinue treatment due to disease progression will be based on iRECIST, while some secondary and exploratory anticancer activity analyses will be based on RECIST 1.1. Scans will be collected and archived centrally to allow for the option of central review.

[0264] analysis After each dosing cohort, the Neuenschwander sequential reassessment method (NCRM) will be used to guide dose escalation of monotherapy and combination therapy. Dose escalation decisions will be based primarily on dose-limiting toxicities (DLTs), but will take into account the totality of clinical safety assessments, PK, and PD data. No formal statistical hypotheses will be tested and analyses will be descriptive. This is a two-arm, open-label, interventional study.

[0265] Number of participants Approximately 100 participants will be enrolled to receive the study intervention. The total number of participants enrolled is an estimate and will depend on the number needed to adequately characterize the DLT profile and determine the RP2D.

[0266] Intervention groups and duration In Arm A (monotherapy), GSK6097608 will be administered IV over approximately 30 minutes to participants under the medical supervision of the investigator or an appropriately qualified designee.

[0267] In Arm B (combination therapy), GSK6097608 will be administered IV first. Dostarlimab will then be administered IV over 30 minutes after the end of the GSK6097608 infusion. Both study interventions will be performed under the medical supervision of the investigator or designee.

[0268] The study will include three periods: screening (assessment up to 28 days prior to first dose), treatment (until disease progression, unacceptable toxicity, death, or withdrawal of consent), and treatment discontinuation and follow-up (90 days). The full period of study participation will begin with signing of the Informed Consent Form (ICF) and will continue through the final protocol-defined follow-up evaluation period. The maximum period of study participation will depend on the duration of the participant's study intervention and will be approximately up to 2 years.

[0269] Tumor Imaging and Disease Assessment Methods and timing of lesion assessment, disease assessment, disease progression, and response criteria will be performed according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RECIST 1.1 will be used in the assessment of disease burden at screening (determination of target and non-target lesions) and as the primary measure of tumor response endpoints. iRECIST will be used by investigators to assess tumor response and progression and make treatment decisions.

[0270] [Sequence table] The CDRs as defined by Kabat are underlined. 42Y073-86F08-1 variable light chain amino acid sequence SEQ ID NO:1 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0271] 42Y073-86F08-1 variable heavy chain amino acid sequence SEQ ID NO:2 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLEWMG GIIPIFGTASYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDVWGQGTTVTVSS

[0272] 42Y073-86F08-1 Variable light chain nucleic acid sequence SEQ ID NO:3 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCA CTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0273] 42Y073-86F08-1 variable heavy chain nucleic acid sequence SEQ ID NO:4 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCAGCTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCACCGCCAGCTACGCC CAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0274] 42Y073-86F04-3 Variable light chain amino acid sequence SEQ ID NO:5 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0275] 42Y073-86F04-3 Variable heavy chain amino acid sequence SEQ ID NO:6 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS YNAIS WVRQAPGQGLEWMG GIIPIMGTARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0276] 42Y073-86F04-3 Variable light chain nucleic acid sequence SEQ ID NO:7 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0277] 42Y073-86F04-3 Variable heavy chain nucleic acid sequence SEQ ID NO:8 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCTACAACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTATGGGCACCGCCAGG TACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0278] 42Y073-86F04-4 Variable light chain amino acid sequence SEQ ID NO:9 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0279] 42Y073-86F04-4 Variable heavy chain amino acid sequence SEQ ID NO:10 QVQLVQSGAEVKKPGSSVKVSCKASGGTFE SEAIS WVRQAPGQGLEWMG GIIPIFGRARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0280] 42Y073-86F04-4 Variable light chain nucleic acid sequence SEQ ID NO:11 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0281] 42Y073-86F04-4 Variable heavy chain nucleic acid sequence SEQ ID NO: 12 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCGAGAGCGAGGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCAGGGCCAGGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0282] 42Y073-86F04-5 Variable light chain amino acid sequence SEQ ID NO: 13 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0283] 42Y073-86F04-5 variable heavy chain amino acid sequence SEQ ID NO:14 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SHAIS WVRQAPGQGLEWMG GIIPIFGRGKYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0284] 42Y073-86F04-5 Variable light chain nucleic acid sequence SEQ ID NO:15 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0285] 42Y073-86F04-5 Variable heavy chain nucleic acid sequence SEQ ID NO:16 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCAGCCACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCAGGGCAAG TACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0286] 42Y073-86F04-6 Variable light chain amino acid sequence SEQ ID NO:17 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0287] 42Y073-86F04-6 variable heavy chain amino acid sequence SEQ ID NO:18 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS GHAIS WVRQAPGQGLEWMG GIIPIFGRARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0288] 42Y073-86F04-6 Variable light chain nucleic acid sequence SEQ ID NO:19 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0289] 42Y073-86F04-6 Variable heavy chain nucleic acid sequence SEQ ID NO: 20 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCGGCCACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCAGGGCCAGGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0290] 42Y073-86F04-18 Variable light chain amino acid sequence SEQ ID NO: 21 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0291] 42Y073-86F04-18 Variable heavy chain amino acid sequence SEQ ID NO:22 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SRAIS WVRQAPGQGLEWMG GIIPIMGTARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0292] 42Y073-86F04-18 Variable light chain nucleic acid sequence SEQ ID NO:23 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0293] 42Y073-86F04-18 Variable heavy chain nucleic acid sequence SEQ ID NO:24 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCAGCAGGGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTATGGGCACCGCCAGG TACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0294] 42Y073-86F04-33 Variable light chain amino acid sequence SEQ ID NO:25 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0295] 42Y073-86F04-33 variable heavy chain amino acid sequence SEQ ID NO:26 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLEWMG GILPIFGRANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0296] 42Y073-86F04-33 Variable light chain nucleic acid sequence SEQ ID NO:27 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0297] 42Y073-86F04-33 variable heavy chain nucleic acid sequence SEQ ID NO: 28 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCAGCTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCCTGCCCATTTTCGGCAGGGCCAACTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0298] 42Y073-86F04-88 variable light chain amino acid sequence SEQ ID NO: 29 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0299] 42Y073-86F04-88 Variable heavy chain amino acid sequence SEQ ID NO:30 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SSAIS WVRQAPGQGLEWMG GIIPIFGRANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0300] 42Y073-86F04-88 Variable light chain nucleic acid sequence SEQ ID NO:31 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0301] 42Y073-86F04-88 Variable heavy chain nucleic acid sequence SEQ ID NO:32 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCAGCAGCGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCAGGGCCAAC TACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0302] 42Y073-86F08-3 Variable light chain amino acid sequence SEQ ID NO:33 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0303] 42Y073-86F08-3 variable heavy chain amino acid sequence SEQ ID NO:34 QVQLVQSGAEVKKPGSSVKVSCKASGGTFV NYAIS WVRQAPGQGLEWMG GIIPALGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0304] 42Y073-86F08-3 Variable light chain nucleic acid sequence SEQ ID NO:35 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0305] 42Y073-86F08-3 Variable heavy chain nucleic acid sequence SEQ ID NO: 36 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCGTGAACTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCGCCCTGGGCACCGCCAACTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0306] 42Y073-86F08-4 Variable light chain amino acid sequence SEQ ID NO: 37 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0307] 42Y073-86F08-4 variable heavy chain amino acid sequence SEQ ID NO:38 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS EYAIH WVRQAPGQGLEWMG NIIPIFGTAGYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0308] 42Y073-86F08-4 Variable light chain nucleic acid sequence SEQ ID NO:39 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCA CTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0309] 42Y073-86F08-4 Variable heavy chain nucleic acid sequence SEQ ID NO:40 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCGAGTACGCCATCCACTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCAACATCATCCCCATTTTCGGCACCGCCGGCTACGCC CAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0310] 42Y073-86F08-8 Variable light chain amino acid sequence SEQ ID NO:41 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0311] 42Y073-86F08-8 Variable heavy chain amino acid sequence SEQ ID NO:42 QVQLVQSGAEVKKPGSSVKVSCKASGGTFW LYAIS WVRQAPGQGLEWMG GIIPQLGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0312] 42Y073-86F08-8 Variable light chain nucleic acid sequence SEQ ID NO:43 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0313] 42Y073-86F08-8 Variable heavy chain nucleic acid sequence SEQ ID NO: 44 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCTGGCTGTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCCAGCTGGGCACCGCCAACTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0314] 42Y073-86F08-17 Variable light chain amino acid sequence SEQ ID NO: 45 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0315] 42Y073-86F08-17 variable heavy chain amino acid sequence SEQ ID NO:46 QVQLVQSGAEVKKPGSSVKVSCKASGGTFR EYAIS WVRQAPGQGLEWMG GIIPVFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0316] 42Y073-86F08-17 Variable light chain nucleic acid sequence SEQ ID NO:47 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCA CTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0317] 42Y073-86F08-17 Variable heavy chain nucleic acid sequence SEQ ID NO:48 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGGGAGTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCGTGTTCGGCACCGCCAACTACGCC CAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0318] 42Y073-86F08-22 variable light chain amino acid sequence SEQ ID NO:49 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQVLHTIT FGGGTKVEIK

[0319] 42Y073-86F08-22 variable heavy chain amino acid sequence SEQ ID NO:50 QVQLVQSGAEVKKPGASVKVSCKASGYTFD SYAMH WVRQAPGQGLEWMG GIIPIFGTAWYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0320] 42Y073-86F08-22 variable light chain nucleic acid sequence SEQ ID NO:51 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0321] 42Y073-86F08-22 Variable heavy chain nucleic acid sequence Sequence number 52 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCTACACCTTCGACAGCTACGCCATGCACTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTTTCGGCACCGCCTGGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0322] 42Y073-86F08-47 Variable light chain amino acid sequence Sequence number 53 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QVLHTIT FGGGTKVEIK

[0323] 42Y073-86F08-47 variable heavy chain amino acid sequence SEQ ID NO:54 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS QYAIH WVRQAPGQGLEWMG VIIPIFGKANYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0324] 42Y073-86F08-47 Variable light chain nucleic acid sequence SEQ ID NO:55 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCA CTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0325] 42Y073-86F08-47 Variable heavy chain nucleic acid sequence SEQ ID NO:56 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCCAGTACGCCATCCACTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGTGATCATCCCCATTTTCGGCAAGGCCAACTACGCC CAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0326] 42Y073-2B04-46 Variable light chain amino acid sequence SEQ ID NO:57 EIVLTQSPATLSLSPGERATLSC RASQSVSSYLA WYQQKPGQAPRLLIY DESK GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQLDNWPIT FGGGTKVEIK

[0327] 42Y073-2B04-46 Variable heavy chain amino acid sequence SEQ ID NO:58 QVQLQQWGAGLLKPSETLSLTCAVYGGSFR RYYWS WIRQPPGKGLEWIG EIDGWGSTNYNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR GGSVDFWSGSDYYYYMDV WGKGATVTVSS

[0328] 42Y073-2B04-46 Variable light chain nucleic acid sequence SEQ ID NO:59 GAGATCGTGCTGACCCAGAGCCCCGCAACCCTGTCCCTGAGCCCCGGCGAAAGGGCCACTCTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTCGCCTGGTACCAGCAGAAGCCCGGCCAGGCCCCTAGGCTGCTGATCTACGACGCCAGCAAGAGGGCCACCGGCATTCCCGCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCCGAGGACTTCGCCGTCTACTACTGCCAGCAGCTGGACAACTGGCCC ATCACCTTCGGGGGCGGCACCAAGGTGGAGATCAAG

[0329] 42Y073-2B04-46 Variable heavy chain nucleic acid sequence SEQ ID NO: 60 CAGGTGCAGCTGCAGCAGTGGGGCGCCGGACTGCTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGTACGGCGGGTCCTTCAGGAGGTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAAGGCCTGGAGTGGATCGGCGAGATCGACGGCTGGGGCAGCACCAACTACAACCCCAGCCTCAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTATTGC GCCAGGGGCGGCAGCGTGGACTTCTGGAGCGGCAGCGACTACTACTACTACATGGACGTGTGGGGCAAGGGCGCCACCGTCACCGTGAGCAGC

[0330] 42Y073-1A01-85 Variable light chain amino acid sequence SEQ ID NO: 61 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQSGVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQSLYPPRT FGGGTKVEIK

[0331] 42Y073-1A01-85 Variable heavy chain amino acid sequence SEQ ID NO:62 QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYPMH WVRQAPGQGLEWMG IINPSGGFTSYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSA

[0332] 42Y073-1A01-85 Variable light chain nucleic acid sequence SEQ ID NO:63 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGA TCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGCCTGTACCCCCCC AGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0333] 42Y073-1A01-85 Variable heavy chain nucleic acid sequence SEQ ID NO:64 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGGCCTCCGGGTACACCTTCACCAGCTACCCCATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGATGGGCATCATCAACCCCAGCGGAGGCTTCACCAGCTACGCCC AGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTACTGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC

[0334] 42Y073-1A01-97 Variable light chain amino acid sequence SEQ ID NO:65 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQSLYPPRT FGGGTKVEIK

[0335] 42Y073-1A01-97 Variable heavy chain amino acid sequence SEQ ID NO:66 QVQLVQSGAEVKKPGASVKVSCKASGYTFT REMEDIES WVRQAPGQGLEWMG IINPAGGYTSYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSS

[0336] 42Y073-1A01-97 Variable light chain nucleic acid sequence SEQ ID NO:67 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGAGCCTGTACCCCCCCAGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0337] 42Y073-1A01-97 Variable heavy chain nucleic acid sequence SEQ ID NO: 68 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGGCCTCCGGGTACACCTTCACCAGGGCCGCCATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGATGGGCATCATCAACCCCGCCGGAGGCTACACCAGCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTAC TGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCT

[0338] 42Y073-1A01-100 Variable light chain amino acid sequence SEQ ID NO: 69 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSLYPPRTFGGGTKVEIK

[0339] 42Y073-1A01-100 Variable heavy chain amino acid sequence SEQ ID NO:70 QVQLVQSGAEVKKPGASVKVSCKASGYTFT TYRMH WVRQAPGQGLEWMG IINPSGGLTQYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSS

[0340] 42Y073-1A01-100 Variable light chain nucleic acid sequence SEQ ID NO:71 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGA TCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGCCTGTACCCCCCC AGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0341] 42Y073-1A01-100 Variable heavy chain nucleic acid sequence SEQ ID NO:72 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGCCTCCGGGTACACCTTCACCACCTACAGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGA TGGGCATCATCAACCCCAGCGGAGGCCTGACCCAGTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTAC TGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCT

[0342] 42Y073-1A01-103 Variable light chain amino acid sequence SEQ ID NO:73 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQSLYPPRT FGGGTKVEIK

[0343] 42Y073-1A01-103 Variable heavy chain amino acid sequence SEQ ID NO:74 QVQLVQSGAEVKKPGASVKVSCKASGYTFT AYQMH WVRQAPGQGLEWMG IINPAGGWTSYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSS

[0344] 42Y073-1A01-103 Variable light chain nucleic acid sequence SEQ ID NO:75 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGAGCCTGTACCCCCCCAGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0345] 42Y073-1A01-103 variable heavy chain nucleic acid sequence SEQ ID NO: 76 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGGCCTCCGGGTACACCTTCACCGCCTACCAGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGATGGGCATCATCAACCCCGCCGGAGGCTGGACCAGCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTACTGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCT

[0346] 42Y073-1A01-126 variable light chain amino acid sequence SEQ ID NO: 77 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSLYPPRT FGGGTKVEIK

[0347] 42Y073-1A01-126 Variable heavy chain amino acid sequence SEQ ID NO:78 QVQLVQSGAEVKKPGASVKVSCKASGYTFT RYNMH WVRQAPGQGLEWMG WINPAGGSTSYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSA

[0348] 42Y073-1A01-126 Variable light chain nucleic acid sequence SEQ ID NO:79 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGCCTGTACCCCCCCAGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0349] 42Y073-1A01-126 Variable heavy chain nucleic acid sequence SEQ ID NO:80 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGGCCTCCGGGTACACCTTCACCAGGTACAACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGATGGGCTGGATCAACCCCGCCGGAGGCAGCACCAGCTACGCCC AGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTACTGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC

[0350] 42Y073-1A01-191 Variable light chain amino acid sequence SEQ ID NO:81 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQSLYPPRT FGGGTKVEIK

[0351] 42Y073-1A01-191 Variable heavy chain amino acid sequence SEQ ID NO:82 QVQLVQSGAEVKKPGASVKVSCKASGYTFT KYRMH WVRQAPGQGLEWMG IINPQGGSTSYAQKFQG RVTTMTRDTTSTSTVYMELSSLRSEDTAVYYCAR ETAYYTTKGNWFDP WGQGTLVTVSA

[0352] 42Y073-1A01-191 Variable light chain nucleic acid sequence SEQ ID NO:83 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGAGCCTGTACCCCCCCAGGACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0353] 42Y073-1A01-191 Variable heavy chain nucleic acid sequence SEQ ID NO: 84 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAAAAGCCCGGCGCCAGCGTGAAGGTCAGCTGCAAGGCCTCCGGGTACACCTTCACCAAGTACAGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTCGAGTGGATGGGCATCATCAACCCCCAGGGAGGCAGCACCAGCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACAAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTATTAC TGCGCAAGGGAGACCGCCTACTACACCACCAAGGGCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC

[0354] 42Y073-86F08-66 Variable light chain amino acid sequence SEQ ID NO: 85 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QVLHTITFGGGTKVEIK

[0355] 42Y073-86F08-66 variable heavy chain amino acid sequence SEQ ID NO:86 QVQLVQSGAEVKKPGSSVKVSCKASGGTFV EIAIS WVRQAPGQGLEWMG GIIPAFGTAQYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0356] 42Y073-86F08-66 Variable light chain nucleic acid sequence SEQ ID NO:87 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCA GGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCT GATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGAC TTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0357] 42Y073-86F08-66 Variable heavy chain nucleic acid sequence SEQ ID NO:88 CAGGTGCAGCTGGTGCAGAGCGGCGCAGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGG CCTCCGGCGGGACCTTCGTGGAGTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTG GATGGGCGGCATCATCCCCGCCTTCGGCACCGCCCAGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATC ACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGT ACTATTGCGCCAGGGGAGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCAC CGTGACTGTGAGCAGC

[0358] 42Y073-86F08-16 variable light chain amino acid sequence SEQ ID NO:89 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QVLHTIT FGGGTKVEIK

[0359] 42Y073-86F08-16 variable heavy chain amino acid sequence SEQ ID NO:90 QVQLVQSGAEVKKPGSSVKVSCKASGGTFN EIAIS WVRQAPGQGLEWMG GIVPVFGTAKYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSS

[0360] 42Y073-86F08-16 Variable light chain nucleic acid sequence SEQ ID NO:91 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0361] 42Y073-86F08-16 Variable heavy chain nucleic acid sequence SEQ ID NO: 92 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAACGAGTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCGTGCCCGTGTTCGGCACCGCCAAGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0362] 42Y073-86F04-23 Variable light chain amino acid sequence SEQ ID NO: 93 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIK

[0363] 42Y073-86F04-23 variable heavy chain amino acid sequence SEQ ID NO:94 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS GYPSY WVRQAPGQGLEWMG GIIPIMGTARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSS

[0364] 42Y073-86F04-23 Variable light chain nucleic acid sequence SEQ ID NO:95 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCAC TGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG

[0365] 42Y073-86F04-23 Variable heavy chain nucleic acid sequence SEQ ID NO:96 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCGGCTACCCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTATGGGCACCGCCAGG TACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGCTGCTGGGCGAGAGCGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC

[0366] CDRL1 amino acid sequence 1 SEQ ID NO:97 RASQSISSYLN

[0367] CDRL1 amino acid sequence 2 SEQ ID NO:98 RASQSVSSYLA

[0368] CDRL2 amino acid sequence 1 SEQ ID NO:99 AASSLQS

[0369] CDRL2 amino acid sequence 2 SEQ ID NO:100 DASKRAT

[0370] CDRL3 amino acid sequence 1 SEQ ID NO:101 QQVLHTIT

[0371] CDRL3 amino acid sequence 2 SEQ ID NO:102 QQPYFSPPT

[0372] CDRL3 amino acid sequence 3 SEQ ID NO:103 QQLDNWPIT

[0373] CDRL3 amino acid sequence 4 SEQ ID NO:104 QQSLYPPRT

[0374] CDRH1 amino acid sequence 1 SEQ ID NO:105 SYAIS

[0375] CDRH1 amino acid sequence 2 SEQ ID NO:106 YNAIS

[0376] CDRH1 amino acid sequence 3 SEQ ID NO:107 SEAIS

[0377] CDRH1 amino acid sequence 4 SEQ ID NO:108 SHAIS

[0378] CDRH1 amino acid sequence 5 SEQ ID NO:109 GHAIS

[0379] CDRH1 amino acid sequence 6 SEQ ID NO:110 SRAIS

[0380] CDRH1 amino acid sequence 7 SEQ ID NO:111 SSAIS

[0381] CDRH1 amino acid sequence 8 SEQ ID NO:112 NYAIS

[0382] CDRH1 amino acid sequence 9 SEQ ID NO:113 EYAIH

[0383] CDRH1 amino acid sequence 10 SEQ ID NO:114 LYAIS

[0384] CDRH1 amino acid sequence 11 SEQ ID NO:115 EYAIS

[0385] CDRH1 amino acid sequence 12 SEQ ID NO:116 SYAMH

[0386] CDRH1 amino acid sequence 13 SEQ ID NO:117 QYAIH

[0387] CDRH1 amino acid sequence 14 SEQ ID NO:118 RYYWS

[0388] CDRH1 amino acid sequence 15 SEQ ID NO:119 SYPMH

[0389] CDRH1 amino acid sequence 16 SEQ ID NO:120 RAAMH

[0390] CDRH1 amino acid sequence 17 SEQ ID NO:121 TYRMH

[0391] CDRH1 amino acid sequence 18 SEQ ID NO:122 AYQMH

[0392] CDRH1 amino acid sequence 19 SEQ ID NO:123 RYNMH

[0393] CDRH1 amino acid sequence 20 SEQ ID NO:124 KYRMH

[0394] CDRH1 amino acid sequence 21 SEQ ID NO:125 GYPIS

[0395] CDRH2 amino acid sequence 1 SEQ ID NO:126 GIIPIFGTASYAQKFQG

[0396] CDRH2 amino acid sequence 2 SEQ ID NO:127 GIIPIMGTARYAQKFQG

[0397] CDRH2 amino acid sequence 3 SEQ ID NO:128 GIIPIFGRARYAQKFQG

[0398] CDRH2 amino acid sequence 4 SEQ ID NO:129 GIIPIFGRGKYAQKFQG

[0399] CDRH2 amino acid sequence 5 SEQ ID NO:130 GILPIFGRANYAQKFQG

[0400] CDRH2 amino acid sequence 6 SEQ ID NO:131 GIIPIFGRANYAQKFQG

[0401] CDRH2 amino acid sequence 7 SEQ ID NO:132 GIIPALGTANYAQKFQG

[0402] CDRH2 amino acid sequence 8 SEQ ID NO:133 NIIPIFGTAGYAQKFQG

[0403] CDRH2 amino acid sequence 9 SEQ ID NO:134 GIIPQLGTANYAQKFQG

[0404] CDRH2 amino acid sequence 10 SEQ ID NO:135 GIIPVFGTANYAQKFQG

[0405] CDRH2 amino acid sequence 11 SEQ ID NO:136 GIIPIFGTAWYAQKFQG

[0406] CDRH2 amino acid sequence 12 SEQ ID NO:137 VIIPIFGKANYAQKFQG

[0407] CDRH2 amino acid sequence 13 SEQ ID NO:138 EIDGWGSTNYNPSLKS

[0408] CDRH2 amino acid sequence 14 SEQ ID NO:139 IINPSGGFTSYAQKFQG

[0409] CDRH2 amino acid sequence 15 SEQ ID NO:140 IINPAGGYTSYAQKFQG

[0410] CDRH2 amino acid sequence 16 SEQ ID NO:141 IINPSGGLTQYAQKFQG

[0411] CDRH2 amino acid sequence 17 SEQ ID NO:142 IINPAGGWTSYAQKFQG

[0412] CDRH2 amino acid sequence 18 SEQ ID NO:143 WINPAGGSTSYAQKFQG

[0413] CDRH2 amino acid sequence 19 SEQ ID NO:144 IINPQGGSTSYAQKFQG

[0414] CDRH2 amino acid sequence 20 SEQ ID NO:145 GIIPAFGTAQYAQKFQG

[0415] CDRH2 amino acid sequence 21 SEQ ID NO:146 GIVPVFGTAKYAQKFQG

[0416] CDRH3 amino acid sequence 1 SEQ ID NO:147 GAGYYGDKDPMDV

[0417] CDRH3 amino acid sequence 2 SEQ ID NO:148 LLGESGMDV

[0418] CDRH3 amino acid sequence 3 SEQ ID NO:149 GGSVDFWSGSDYYYYMDV

[0419] CDRH3 amino acid sequence 4 SEQ ID NO:150 ETAYYTTKGNWFDP

[0420] PD-1 antagonist CDRH1 SEQ ID NO:151 SYDMS

[0421] PD-1 antagonist CDRH2 SEQ ID NO:152 TISGGGSYTYYQDSVKG

[0422] PD-1 antagonist CDRH3 SEQ ID NO:153 PYYAMDY

[0423] PD-1 antagonist CDRL1 SEQ ID NO:154 KASQDVGTAVA

[0424] PD-1 antagonist CDRL2 SEQ ID NO:155 WASTLHT

[0425] PD-1 antagonist CDRH3 SEQ ID NO:156 QHYSSYPWT

[0426] PD-1 antagonist alternative CDRL3 SEQ ID NO:157 QHYNSYPWT

[0427] PD-1 antagonist heavy chain variable region SEQ ID NO:158 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS

[0428] PD-1 antagonist light chain variable region SEQ ID NO:159 DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK

[0429] PD-1 antagonist monoclonal antibody heavy chain SEQ ID NO:160 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0430] PD-1 antagonist monoclonal antibody light chain SEQ ID NO:161 DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0431] PD-1 antagonist heavy chain sequence with N380D modification SEQ ID NO:162 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESDGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0432] PD-1 antagonist light chain sequence with N385D modification SEQ ID NO:163 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEDNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0433] PD-1 antagonist heavy chain sequence with N380D and N385D modifications SEQ ID NO:164 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGT TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESDGQPEDNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0434] 42Y073-86F08-66 full-length heavy chain amino acid sequence SEQ ID NO:165 QVQLVQSGAEVKKPGSSVKVSCKASGGTFV EIAIS WVRQAPGQGLEWMG GIIPAFGTAQY AQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTV SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0435] 42Y073-86F08-66 full-length light chain amino acid sequence SEQ ID NO:166 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPS RFSGSGSGTDFTLTISSLQPEDFATYYC QVLHTIT FGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0436] 42Y073-86F08-66 full-length heavy chain DNA sequence SEQ ID NO:167 ATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG

[0437] 42Y073-86F08-66 full-length light chain DNA sequence Sequence number: 168 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC

[0438] 42Y073-86F08-16 full-length light chain amino acid sequence SEQ ID NO: 169 DIQLTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QVLHTIT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0439] 42Y073-86F08-16 full-length heavy chain amino acid sequence SEQ ID NO:170 QVQLVQSGAEVKKPGSSVKVSCKASGGTFN EIAIS WVRQAPGQGLEWMG GIVPVFGTAKYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR GAGYYGDKDPMDV WGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0440] 42Y073-86F08-16 full-length light chain DNA sequence SEQ ID NO:171 GACATCCAGCTGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCA CTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGGTGCTGCACACCATCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAG CGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC

[0441] 42Y073-86F08-16 full-length heavy chain DNA sequence SEQ ID NO: 172 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAACGAGTACGCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCGTGCCCGTGTTCGGCACCGCCAAGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAACTCAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTATTGCGCCAGGGGCGCCGGCTACTACGGCGACAAGGACCCCATGGACGTGTGGGGCCAGGGCACCACCGTGACTGTGAGCAGC GCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG

[0442] 42Y073-86F04-23 full-length light chain amino acid sequence SEQ ID NO:173 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQPYFSPPT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0443] 42Y073-86F04-23 full-length heavy chain amino acid sequence SEQ ID NO:174 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS GYPSY WVRQAPGQGLEWMG GIIPIMGTARYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR LLGESGMDV WGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0444] 42Y073-86F04-23 full-length light chain DNA sequence SEQ ID NO:175 GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGAGACAGGGTGACCATCACCTGCAGGGCCAGCCAGTCCATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCAAGCTCACTGCAGAGCGGCGTGCCCTCTAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATC AGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCCCTACTTCAGCCCCCCCACTTTCGGCGGCGGCACCAAGGTGGAGATTAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC

[0445] Full-length heavy chain DNA sequence of 42Y073-86F04-23 Sequence number: 176 CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCTCCGGCGGGACCTTCAGCGGCTACCCCATCAGCTGGGTGAGGCAGGCTCCCGGACAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATTATGGGCACCGCCAGGTACGCCCAGAAGTTCCAGGGAAGGGTCACCATCACCGCCGACGAGAGC

[0446] CD155-fc amino acid sequence used in the examples (the bold sequence is the mature CD155 ECD (extracellular domain) without the leader sequence, the remainder is the human IgG1 Fc region). SEQ ID NO:177 [Table 11]

[0447] CD155 amino acid sequence (native leader sequence underlined, transmembrane and cytoplasmic portions in bold). SEQ ID NO:178 [Table 12]

[0448] Human IgG1 Fc region amino acid sequence SEQ ID NO:179 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0449] Human IgG1 Fc region nucleic acid sequence SEQ ID NO:180 GCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG

Claims

1. 1. A CD96 binding protein comprising: (a) any one or combination of CDRs selected from (i) CDRH1, CDRH2, CDRH3 from SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, and 94, and / or CDRL1, CDRL2, CRDL3 from SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, and 93; or (ii) a CDR variant of (i) having one, two or three amino acid modifications; or (b) a VH region comprising a sequence at least 80% identical to the sequence of SEQ ID NO: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, or 94; and / or a VL region comprising a sequence at least 80% identical to the sequence of SEQ ID NO: 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, or 93. A CD96 binding protein comprising:

2. The CDR of (a)(i) is (1) The CD96 binding protein of claim 1, which is a CDRH1 selected from SEQ ID NOs: 105-125; a CDRH2 selected from SEQ ID NOs: 126-146; and / or a CDRH3 selected from SEQ ID NOs: 147-150; a CDRL1 selected from SEQ ID NOs: 97-98; a CDRL2 selected from SEQ ID NOs: 99-100; and / or a CDRL3 selected from SEQ ID NOs: 101-104.

3. 3. The CD96 binding protein of claim 1 or 2, wherein the binding protein comprises a CDRH3 that is 100% identical to SEQ ID NO: 147, 148, 149, or 150.

4. the binding protein is a CDRH1 that is 100% identical to SEQ ID NO: 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, or 125; 4, 145, or 146; and / or a CDRH3 that is 100% identical to SEQ ID NO: 147, 148, 149, or 150; a CDRL1 that is 100% identical to SEQ ID NO: 97 or 98; a CDRL2 that is 100% identical to SEQ ID NO: 99 or 100; and a CDRL3 that is 100% identical to SEQ ID NO: 101, 102, 103, or 104.

5. 5. The CD96 binding protein of any one of claims 1 to 4, wherein all six CDRs are present in the binding protein.

6. A CD96 binding protein comprising the following six CDRs: CDRH1 of SEQ ID NO: 115; CDRH2 of SEQ ID NO: 145; and CDRH3 of SEQ ID NO: 147; and CDRL1 of SEQ ID NO:97; CDRL2 of SEQ ID NO:99; and CDRL3 of sequence number:

101.

7. The binding protein is A VH region that is 75% identical to SEQ ID NO:86; and / or The CD96 binding protein of claim 6, comprising a VL region that is 75% identical to SEQ ID NO:

85.

8. The binding protein is A VH region that is 100% identical to SEQ ID NO:86; and / or A CD96 binding protein according to any one of claims 1 to 7, comprising a VL region that is 100% identical to SEQ ID NO:

85.

9. The CD96 binding protein of any one of claims 1 to 8, wherein the binding protein comprises a synthetic polypeptide, a humanized sequence, or a chimeric sequence.

10. A CD96 binding protein according to any one of claims 1 to 9, wherein the protein binds to CD96 with a binding affinity (KD) equal to or better than that of CD155, or is capable of preventing or displacing CD155 from binding to CD96.

11. A CD96 binding protein according to any one of claims 1 to 10, which binds to CD96 with a binding affinity (KD) of at least about 30 nM.

12. A CD96 binding protein according to any one of claims 1 to 11, which is an antibody and comprises an antibody Fc region capable of binding to an Fc gamma receptor and / or promoting IFN gamma release.

13. The CD96 binding protein of claim 12, wherein the Fc region is wild-type IgG1 Fc or a functional variant thereof.

14. 1. An antibody, wherein the binding protein comprises a heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO:165; and / or a light chain that is 100% identical to the amino acid sequence of SEQ ID NO:

166.

15. 1. An antibody, wherein the binding protein comprises a heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO:170; and / or a light chain that is 100% identical to the amino acid sequence of SEQ ID NO:

169.

16. 1. An antibody, wherein the binding protein comprises a heavy chain that is 100% identical to the amino acid sequence of SEQ ID NO:174; and / or a light chain that is 100% identical to the amino acid sequence of SEQ ID NO:

173.

17. A nucleic acid sequence encoding a CD96 binding protein as defined in any one of claims 1 to 16.

18. 18. The nucleic acid sequence of claim 17, wherein the sequence comprises SEQ ID NO: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 167, 172, or 176 encoding a heavy chain; and / or SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, 79, 83, 87, 91, 95, 168, 171, or 175 encoding a light chain.

19. 19. An expression vector comprising a nucleic acid sequence according to claim 17 or 18.

20. 20. The expression vector of claim 19, selected from the following: (i) a vector encoding the nucleic acid sequence of a heavy chain of SEQ ID NO: 167 and the nucleic acid sequence of a light chain of SEQ ID NO: 168, (ii) a vector encoding the nucleic acid sequence of a heavy chain of SEQ ID NO: 172 and the nucleic acid sequence of a light chain of SEQ ID NO: 171, and (iii) a vector encoding the nucleic acid sequence of a heavy chain of SEQ ID NO: 176 and the nucleic acid sequence of a light chain of SEQ ID NO:

175.

21. A recombinant host cell comprising a nucleic acid sequence according to claim 17 or 18, or an expression vector according to claim 19 or 20.

22. A method for producing a CD96 binding protein comprising culturing a host cell described in claim 21 under conditions suitable for expression of the nucleic acid sequence or vector, thereby producing a polypeptide comprising a CD96 binding protein.

23. 23. A CD96 binding protein produced by the method of claim 22.

24. A cell line engineered to express a CD96 binding protein according to any one of claims 1 to 16.

25. A pharmaceutical composition comprising a CD96 binding protein according to any one of claims 1 to 16 and a pharma- ceutically acceptable excipient.

26. 26. The pharmaceutical composition of claim 25, comprising a CD96 binding protein of any one of claims 6, 8, or 14-16 and a pharma- ceutically acceptable excipient.

27. A method for treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CD96 binding protein described in any one of claims 1 to 16 or a pharmaceutical composition described in any one of claims 25 to 26.

28. A method for treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CD96 binding protein of any one of claims 6, 8, or 14-16.

29. The method of claim 27 or 28, further comprising determining whether the subject expresses CD96.

30. A CD96 binding protein according to any one of claims 1 to 16 or a pharmaceutical composition according to any one of claims 25 to 26 for use in therapy.

31. A CD96 binding protein according to any one of claims 1 to 16, or a pharmaceutical composition according to any one of claims 25 to 26, for use in the treatment of a disease in a subject.

32. The CD96 binding protein for use according to claim 31 , wherein the patient is a human subject.

33. A CD96 binding protein according to claims 31 to 32 for use in treating solid tumors.

34. 33. The CD96 binding protein for use according to claim 31 or 32, wherein the protein is an antibody according to claims 14 to 16 and the solid tumour is selected from ovarian, lung (e.g. NSCLC), gastric, bladder, colorectal, liver (e.g. HCC), renal (e.g. RCC) and head and neck squamous cell carcinoma (HNSCC).

35. 27. Use of a CD96 binding protein according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 25 or 26, in the manufacture of a medicament for use in the treatment of a disease.

36. The pharmaceutical composition of claim 25 or 26, further comprising a PD-1 antagonist and / or an anti-TIGIT antibody.

37. 37. The pharmaceutical composition of claim 36, wherein the PD-1 antagonist is an antibody comprising the heavy chain sequence of SEQ ID NO: 160 and the light chain sequence of SEQ ID NO:

162.

38. The method of claim 27 or 28, further comprising administering a PD-1 antagonist and / or an anti-TIGIT antibody.

39. 39. The method of claim 38, wherein the disease is cancer and the CD96 binding protein and the PD-1 antagonist and / or anti-TIGIT antibody are administered to a patient, such as a human patient, by a route in which they are administered simultaneously or sequentially in any order.

40. 40. The method of claim 39, wherein the cancer is a solid tumor and the PD1 antagonist is an antibody comprising the heavy chain sequence of SEQ ID NO: 160 and the light chain sequence of SEQ ID NO:

162.

41. 41. The method of claim 40, wherein the solid tumor is selected from ovarian, lung (e.g., NSCLC), gastric, bladder, colorectal, liver (e.g., HCC), renal (e.g., RCC), and head and neck squamous cell carcinoma (HNSCC).

Citation Information

Patent Citations

  • Immune receptor modulation for treating cancer and viral infections

    JP2016530267A

  • Immune receptor modulation for treating cancer and viral infections

    JP2016530268A

  • Genetically modified NK-92 cells with decreased CD96 / tigit expression

    WO2018129346A1

  • CD96-binding agents as immunomodulators

    WO2019030377A1